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Normal hypothalamopituitary development is closely related to that of the forebrain and is dependent
uponacomplexgeneticcascadeoftranscriptionfactorsandsignalingmoleculesthatmaybeeitherintrinsic
orextrinsictothedevelopingRathke’spouch.Thesefactorsdictateorgancommitment,celldifferentiation,
and cell proliferation within the anterior pituitary. Abnormalities in these processes are associated with
congenital hypopituitarism, a spectrum of disorders that includes syndromic disorders such as septo-optic
dysplasia, combined pituitary hormone deficiencies, and isolated hormone deficiencies, of which the com-
monest is GH deficiency. The highly variable clinical phenotypes can now in part be explained due to
research performed over the last 20 yr, based mainly on naturally occurring and transgenic animal models.
Mutations in genes encoding both signaling molecules and transcription factors have been implicated in
the etiology of hypopituitarism, with or without other syndromic features, in mice and humans. To date,
mutations in known genes account for a small proportion of cases of hypopituitarism in humans. However,
these mutations have led to a greater understanding of the genetic interactions that lead to normal
pituitary development. This review attempts to describe the complexity of pituitary development in the
rodent, with particular emphasis on those factors that, when mutated, are associated with hypopituitarism
in humans. (Endocrine Reviews 30: 790–829, 2009)
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C
ongenital hypopituitarism (CH) is a syndrome with a
widevariationinseverityandwithmanyunderlying
causes. It may present early in the neonatal period or later
in childhood. It can be associated with single or multiple
pituitary hormone deficiencies, and the endocrinopathy
can evolve to include other hormonal deficits. These con-
ditionsareoftenassociatedwithsignificantmorbidityand
occasional mortality, and despite many advances and in-
creased understanding of some of the genetic mechanisms
involved, their etiology remains unknown in the majority
of cases. The frequent association of CH with other ab-
normalities,notablyoftheeyeandforebrain,suggeststhat
many cases are the result of disordered embryogenesis be-
cause these are all structures that depend on normal de-
velopment of the anterior midline. The genetic cascade of
signaling molecules and transcription factors thought to
orchestrate development of the pituitary, but also of the
surrounding regions, is gradually being pieced together.
However, the definitive identity of mutant genes and/or
their relationship with phenotypes remain to be deter-
mined in the majority of cases.
Nevertheless, as we describe in this review, mutations
inanumberofdevelopmentalgeneshavebeenlinkedwith,
andprobablyaccountfor,severalcombinedpituitaryhor-
mone deficiency (CPHD) syndromes, often in association
withanumberofextrapituitarydefectssuchasopticnerve
hypoplasia, anophthalmia/microphthalmia, and fore-
brain defects such as agenesis of the corpus callosum and
absence of the septum pellucidum. Additionally, muta-
tionsinanumberofgenesthatareassociatedwithcellular
differentiation, proliferation, or hormone production
have been discovered in association with isolated hor-
mone deficiencies. This review will describe the current
stateofknowledgeinourunderstandingoftheetiologyof
congenital CPHD in both mouse and human. In doing so,
we cover a wide range of factors implicated in pituitary
development and attempt to convey the rapid progress in
understanding made particularly over the last few years,
while also highlighting how much more remains to be
learned.
II. Embryonic Development of the Mouse
Pituitary Gland
A. Gross structure and function of the mature
pituitary gland
The pituitary gland is a central regulator of growth,
reproduction, and endocrine physiology and functions to
relay signals from the hypothalamus to various target or-
gans. The hypothalamus is the principal neural structure
regulating homeostasis in vertebrates and coordinates
complex signals from other regions of the brain and the
periphery to monitor and maintain the body’s internal
balance. Its primary neuroendocrine output is via neural
terminal arborizations in the median eminence, releasing
factorsthatcontrolthereleaseofhormonesfrompituitary
endocrine cells. It is also likely to provide an equally im-
portanttrophicstimulustothemaintenanceandplasticity
of the gland, although these factors are much less under-
stood. The pituitary, in turn, signals to peripheral organs
to regulate vital processes such as growth, puberty, me-
tabolism, stress responses, reproduction, and lactation.
Theglandissituatedwithinthesellaturcica,arecessinthe
sphenoid bone, at the base of the brain. The mature pitu-
itary gland is comprised of the adenohypophysis (consist-
ing of the anterior and intermediate lobes) and the neu-
rohypophysis(posteriorlobe),whicharefunctionallyand
morphologically distinct structures whose close apposition
nevertheless raises intriguing developmental and functional
possibilities that are yet to be seriously explored.
The anterior lobe of the pituitary secretes hormones
from five different specialized hormone-producing major
cell types. In humans, in contrast to the mouse, the inter-
mediate lobe largely disappears during embryogenesis
with essentially no intermediate lobe in the human pitu-
itary, although the mechanism underlying this species dif-
ference is unclear. This simplified description conceals
rather more complex cellular relationships because there
are subpopulations within the same hormone cell types
[e.g., lactotropes (1)] and subsets of cells that coexpress
morethanonehormone(e.g.,somatomammotropes).The
proportion of these coexpressing cells can alter under dif-
ferent physiological (2) or pathological conditions (3).
Their adult function can be selectively regulated (1), and
it is probable that they are also specified by genetic cas-
cades that extend from fetal to adult life; factors such as
Ikaros, that might be involved in such coregulation, have
been identified (4). The processes determining cell fate,
migration patterns, and final location of the different
hormone-producing cells during development of the em-
bryonic Rathke’s pouch (RP) into the adult anterior lobe
requires a correct genetic program, and individual gene
deletionscanresultinmisspecificationand/ormislocation
ofcells,althoughthesesometimesstillachieveaterminally
differentiated hormone phenotype (5–7).
The posterior lobe contains the terminal axonal projec-
tionsofmagnocellularneuronsfromtheparaventricularand
supraoptic nuclei of the hypothalamus and specialized sup-
portive astroglia known as pituicytes, which surround the
projections. The magnocellular neurons produce oxytocin,
required during parturition and lactation, and arginine va-
sopressin,whichisinvolvedintheregulationofosmoticbal-
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terminals within the posterior pituitary where they are re-
leased as required under hypothalamic control.
Hypothalamic factors are rapidly transported via the
hypophyseal portal blood system to the adenohypophysis
wheretheyregulateendocrinecellproliferation,hormone
synthesis, and hormone release from all the pituitary cell
types. Classically, these factors are thought of as specific
secretagogues, defined by the specificity of receptors on
their target cells. However, this is an oversimplification
because there are a much larger number of peptides and
other factors known to be coexpressed in subsets of these
hypophysiotropic neurons (8). These are also transported
and released into portal blood, probably in much smaller
quantities than the hypophysiotropic peptides, and may
modulatethesecretionofanteriorpituitaryhormonesand
possibly regulate anterior pituitary plasticity.
The neural and vascular connections are carried by the
pituitary stalk, which is responsible for conveying all the in-
formation from the hypothalamus to the pituitary gland.
This is a vulnerable essential bridge between brain and pitu-
itary, and any damage to the pituitary stalk, e.g., through
childbirth or other physical head trauma throughout life,
results in both anterior and posterior pituitary dysfunction,
although to a surprisingly variable extent. The stalk can be
visualized noninvasively using magnetic resonance imaging
(MRI)inbothrodentsandhumans,andflowcanbeimaged
directly using fluorescence in rodents (I. C. A. F. Robinson,
unpublisheddata).Thepresenceorabsenceofanintactstalk
or ectopic localization of the posterior lobe on imaging is an
importantpartofthedescriptionofthephenotypeinhuman
pituitary dysfunction syndromes.
B. Morphogenesis of the pituitary gland
The three lobes of the mature pituitary gland have a
dualembryonicorigin;theanteriorandintermediatelobes
are derived from oral ectoderm, whereas the posterior pi-
tuitaryoriginatesfromtheinfundibulum,aspecificregion
ofthedevelopingcentralnervoussystem(CNS)thatforms
in the midline of the ventral diencephalon. This review
focuses on the mouse as a model organism for pituitary
developmentinmammals,giventheincreasingnumberof
mouse mutants that have been analyzed in which mor-
phogenesis of the pituitary has been affected. However,
fate map studies have shown that these processes are sim-
ilar in all vertebrate species studied, including zebrafish,
amphibians, chick, and rodents (9–13).
In the mouse, the first sign of pituitary development
occursat7.5dayspostcoitum(dpc)withthedevelopment
of the hypophyseal placode, a thickening of the ectoderm
in the midline of the anterior neural ridge. It is already
associated at this stage with the presumptive hypotha-
lamic territories, posteriorly adjacent, as described in
chick(14,15).Duringthenext24h,astheanteriorneural
tubebendsandrapidlyexpands,thehypophysealplacode
is displaced ventrally, within the ectoderm at the roof of
thefutureoralcavity.Atapproximately9dpc,theplacode
forms a rudimentary Rathke’s pouch, the primordium
of the anterior and intermediate lobe. By 10.5 dpc, a
restricted region of the ventral diencephalon above
thepouchgivesrisetotheinfundibulumfromwhichthe
posterior pituitary and pituitary stalk will derive. The
juxtaposition of Rathke’s pouch and the diencephalon
is maintained throughout the early stages of pituitary or-
ganogenesis. This close relationship is required for tissue
interactions between neural and oral ectoderm, which are
critical for the initial stages of pituitary specification. By
10.5 dpc, the pouch is fully developed, and at 12.5 dpc it
iscompletelyseparatedfromtheunderlyingoralectoderm
(Fig. 1). The lumen of the pouch persists as the pituitary
cleft,separatingtheanteriorandintermediatelobesinthe
mature gland. The iterative nature of the inductive inter-
actionsrequiredforpituitarymorphogenesismakesitvery
FIG 1. Mouse pituitary development in sagittal section. Stages of development are indicated in dpc. AL, Anterior lobe; AN, anterior neural pore;
DI, diencephalon; F, forebrain; H, heart; HB, hindbrain; I, infundibulum; IL, intermediate lobe; MB, midbrain; N, notochord; NP, neural plate; O,
oral cavity; OC, optic chiasma; OM, oral membrane; P, pontine flexure; PL, posterior lobe; PO, pons; PP, prechordal plate; RP, Rathke’s pouch; SC,
sphenoid cartilage. [Adapted from H. Z. Sheng and H. Westphal: Trends Genet 15:236–240, 1999 (317), with permission from Elsevier.]
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turn,suchmutationscanbeinformativeastotheunderlying
mechanisms driving invagination and shaping of the pouch
(16),cellmigration,tissuepatterning,andthespecificationof
individual cell fates. Although much remains to be learned,
we discuss the current state of knowledge below.
C. Endocrine cellular differentiation in the developing
pituitary gland
The definitive Rathke’s pouch comprises proliferative
progenitors that will gradually relocate ventrally, away
from the lumen as they differentiate. A proliferative zone
containing progenitors is maintained in the embryo in a
perilumenal area and was recently found to persist in the
adult (17, 18). Ventrally, relocalization is associated with
cell cycle exit (19), and it is not known whether this is an
active migration event or a passive process of cells driven
away by new cells proliferating in the perilumenal area.
The earliest phenotypic marker of differentiation within
the anterior pituitary is the expression of Cga, the gene en-
coding -glycoprotein subunit (GSU), which appears at
11.5 dpc in a restricted patch of cells in the ventral region of
Rathke’s pouch. These GSU-positive cells also express the
transcriptionfactorIslet-1(Isl1)andcorrespondtoprospec-
tive thyrotropes, which differentiate after initiating expres-
sion of Tshb at 12.5 dpc. However, this early population of
thyrotropesisshort-livedanddisappearsatbirth(20–22).In
thematureadultpituitary,Cgaexpressionisonlydetectedin
the thyrotrope and gonadotrope lineages (20).
At12.5dpc,corticotropecellsstarttodifferentiateina
domainjustdorsaltothyrotropes,producingproopiomel-
anocortin (POMC) (22, 23). In the intermediate lobe, as
development proceeds, Pomc-expressing cells begin to be
detected at 14.5 dpc with gradually increasing expression
inmelanotropes(21).Definitivethyrotropesareobserved
at 14.5 dpc, characterized by the expression of Tshb in a
restricted number of cells within the anterior lobe. The
expression of Gh and Prl marks the differentiation of so-
matotrope and lactotrope lineages, respectively, begin-
ning at 15.5 dpc with the number of somatotropes in-
creasing dramatically and extending throughout the
central and lateral areas of the anterior lobe. Lactotropes
remainlocalizedtoamorerestrictedmedialzoneadjacent
to the ventral surface of the intermediate lobe. The gonado-
tropes are the last cell type to emerge, beginning at 16.5 dpc
with the onset of Lhb expression followed by Fshb 1 d later.
Inevitably, much of this description relies on the use of
hallmark differentiation markers to identify cell types.
However, recent unpublished birthdating studies (S.
Camper and S. Davis, Department of Human Genetics,
University of Michigan, personal communication) imply
that the first waves of many endocrine cell types may be
specified earlier and then migrate some distance before
these markers are expressed. This raises the question of
whether there are sorting cues for migrating cells leaving
progenitor pools, and how they end up in the three-
dimensional homotypic networks, shown recently in the
adult mouse pituitary gland (24). Many developmental
studies of the pituitary concentrate their analysis by care-
ful registration of sections in the midline to permit com-
parisonsofanatomicalsectionsovertime.However,these
are likely to have given a very incomplete description of cel-
lular distribution in three dimensions, especially because the
majority of endocrine cells end up in the lateral rather than
medial portions of the gland. Advanced imaging and recon-
structiontechniques,combinedwithfluorescenttagsfordif-
ferent endocrine cell populations, will likely change our
views on the way the gland assembles its networks of cells
and maintains these through cell turnover and replacement
(P. Mollard, Institute of Functional Genomics, Montpelier,
France, personal communication).
D. Mouse genetic models unravel aspects of
pituitary development
The existence of spontaneous mutations and the ease of
generating engineered mutant strains of mice that exhibit
disrupted pituitary development place the mouse as the ma-
jor model for studying pituitary development. We will con-
sider several of the genes and their protein products that are
presentfromearlystagesofpituitarydevelopmentandwhich
are required endogenously within Rathke’s pouch progeni-
tor cells for their maintenance and proliferation. Next, we
will discuss those that are active within cells of the ventral
diencephalon, but which are required for the induction, re-
gionalization, and maintenance of Rathke’s pouch. Finally,
we will review some of the molecules involved in endocrine
cell differentiation from 12.5 dpc, i.e., after Rathke’s pouch
isfullydevelopedandhasseparatedfromtheoralectoderm.
Naturally occurring mutations and targeted ablation of sev-
eralhypothalamichormonesincludingGnRH,GHRH,and
TRH has shown that mice lacking these peptide hormones
generally have normal pituitary development. Hormone de-
ficiencies and the associated effects on downstream targets
fortheserespectivefactorsdevelopafterbirthandarebeyond
thescopeofthisreview(25–28).Similarly,thedescriptionof
isolated hormonal deficiencies will not be reviewed because
most of the effects of these hormonal deficiencies are only
observed postnatally.
III. Factors and Signaling Pathways Present in
the Pituitary Primordium and Initially
Involved in Its Formation and Maintenance
A. SIX homeodomain proteins
These proteins contain a DNA binding homeodomain
homologous to that of Drosophila sine oculus protein.
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eitheractivateorrepresstranscription.Thesefactorswork
inacomplexnetworkwithotherproteins,includingEYA,
and DACH (encoded by the mammalian homologs of the
Eyes absent and dachshund genes in Drosophila). EYA is
aphosphatase,whereasDACHisabletorecruitcorepres-
sors, therefore, depending on the activity of the former,
transcriptioniseitherinducedorrepressed.Thistranscrip-
tion factor network is iteratively used during organogen-
esis; retinal cell determination is a well-characterized ex-
ample(29–31).TheSIX3/6proteinscanalsointeractwith
the Groucho family of transcriptional repressors (32, 33),
which implies yet further links with, e.g., Wingless-type
MMTV integration site family (WNT) signaling pathways.
Four members of the SIX family are expressed during
pituitarydevelopment;buttheexactroleoftheseproteins
is difficult to determine due to likely functional redun-
dancy between them (Six1 and 4) and the severity of the
phenotype affecting anterior forebrain structures in
mouse mutants (Six3). The first demonstration of a role
for these proteins in pituitary development emerged from
studies on Six6. This is first expressed in the invaginating
pouch, but it soon becomes restricted dorsally in the peri-
lumenalregion,wherecellproliferationcontinues,distant
from regions involved in differentiation. In the adult pi-
tuitary, the protein is still strongly expressed (K. Rizzoti,
unpublished observations), implying a potential continu-
ingroleinpituitaryplasticity.Six6isalsoexpressedinthe
developing eye and hypothalamus (31, 34). Liveborn
Six6
/ mice possess hypoplastic pituitaries, likely due to
an early impairment of progenitor proliferation (12). Ar-
guing by analogy with the retinal phenotype seen in the
same animals, the reduced pituitary proliferation is
strongly suggestive of a lack of repression of cell cycle
kinase inhibitors such as p27kip1 whose promoter is di-
rectly bound in vivo by the SIX6/DACH1 complex (31).
In contrast, SIX3 heterozygous deletion (in Six3
/;
Hesx1
/ embryos) has recently been linked to increased
cell proliferation (see Section III.B and Ref. 35).
To date, disease-causing mutations in SIX6 have not
beenidentifiedinhumanpatientswitheithereyedefectsor
pituitary hormone deficiencies (M. T. Dattani, unpub-
lished observations; and Ref. 36).
B. Paired-like homeodomain proteins
1. Hesx1
The transcription factor HESX1 is a member of the
paired-like class of homeodomain proteins (37), and it
functionsasatranscriptionalrepressor(38,39).TLE1,the
mammalianorthologoftheDrosophilaproteinGroucho,
and the nuclear corepressor N-COR both bind to HESX1
to exert repression (38). DNA methyltransferase 1 is also
capable of partnering with HESX1 to repress transcrip-
tion, possibly through CpG methylation of HESX1 target
genes(40).Hesx1isoneoftheearliestmarkersofRathke’s
pouch, initially present in the anterior neural ridge mid-
line, where the hypophyseal placode develops, and in the
adjacent rostral neural plate, a region fated to form the
forebrain and ventral diencephalon. It becomes restricted
to Rathke’s pouch by 9 to 9.5 dpc, where expression is
maintained until 13.5 dpc (41, 42). Its down-regulation is
absolutelyrequiredforcelldeterminationtooccur,inpar-
ticular for the related paired-like homeodomain activator
Prophet of Pit1 (PROP1) to promote these events (see be-
low). Activation of the 5Hesx1 promoter by the LIM
homeodomain proteins Lhx1 and Lhx3 (see below) is re-
quiredforitsearlyexpression,whereasits3downstream
regioncontainselementsbothnecessaryandsufficientfor
later expression in the developing Rathke’s pouch (43).
Hesx1 is essential for normal forebrain development,
andmicewithahomozygoustargeteddisruptionofHesx1
display a range of forebrain defects (44, 45). The most
severely affected Hesx1 null embryos exhibited a signifi-
cant reduction in anterior forebrain (AFB) structures, es-
pecially of midline telencephalic commissural tracts such
as the corpus callosum and anterior commissure and of
olfactory bulbs, fully penetrant eye defects ranging from
microphthalmia to anophthalmia, and absence of the in-
fundibulum, in addition to dysmorphology of Rathke’s
pouch (45, 46). Andoniadou et al. (45) have shown that
thereductionofAFBtissueinthenullmutantsiscausedby
the posteriorization of AFB precursors at early somite
stages. This in turn is related to the ectopic activation of
WNT/-catenin signaling in the prospective AFB. Al-
though the pituitary gland is severely dysplastic and cel-
lularproliferationisenhanced,terminaldifferentiationof
the hormone-producing cell types is not affected at later
stagesofdevelopment(38).Asmallpercentage(5%)ofthe
most severely affected neonates are reported to lack an
anterior pituitary gland (38). However, recent studies
have shown that, in mice bearing a homozygous null mu-
tation in Hesx1 (Hesx1
R160/R160C) that were severely af-
fected with defects of the telencephalon, eyes, and cranio-
facial structures, the anterior pituitary was ectopically
located in the roof of the nasopharyngeal cavity, as was
also observed in Hesx1
/ embryos (47). In contrast, the
moremildlyaffectedhomozygousmutantsshowthepres-
ence of a Rathke’s pouch that is correctly located, albeit
one that is morphologically abnormal with additional bi-
furcations and cell overproliferation. This results in the
apparent formation of multiple pituitary glands (38).
However, postnatally the overgrown gland becomes hy-
poplastic (38), perhaps due to defects in the hypothala-
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natally and it is also affected by Hesx1 deletion (35).
Recently, embryos heterozygous for both Hesx1 and
Six3 null mutations were shown to display a phenotype
reminiscent of that of mildly affected Hesx1
/ em-
bryos. These show increased cell proliferation in the
pouch and a hyperplastic, dysmorphic gland, and it has
been suggested that derepression of the WNT pathway
could be involved (35). Thus both HESX1 and SIX3
seem to control progenitor proliferation in the same or
parallel pathways, and the later switch of expression
betweentherepressorHESX1andtheactivatorPROP1
is an important step toward proper cell determination
(see Section V).
The forebrain, eye, and pituitary deficits identified in
the Hesx1 null mutants subsequently led to the identifi-
cation of mutations in the human homolog HESX1 in
patients with various forms of hypopituitarism including
septo-optic dysplasia (SOD), CPHD, and isolated GH de-
ficiency (IGHD) (46, 48, 49).
2. Otx2
OTX2 is a homolog of the Drosophila orthodenticle
protein.Inmammalstherearetworelatedproteins,OTX1
and OTX2, and their requirement for the formation of
anterior structures has been conserved throughout evolu-
tion from flies to mice (for review, see Ref. 50).
In the mouse, Otx2 is expressed early in development,
and in its absence gastrulation is impaired. As a conse-
quence, mutant embryos lack anterior structures corre-
sponding to the future head (51). Later in development, it
is still required for maintenance of the forebrain (52, 53).
Although its role during pituitary development has not
been precisely investigated, its requirement in anterior
structures implies that it is also necessary for Rathke’s
pouchdevelopment.Itisinparticularnecessaryforcorrect
Hesx1 expression in the forebrain (54).
Recently, mutations in OTX2 have been identified in




PITX1 contains a DNA binding homeodomain related
to that of Drosophila bicoid and orthodenticle (55, 56).
There are three Pitx proteins in mammals, and they play
important roles in different tissues during embryogenesis
(57). Interaction between PITX1 and the pituitary tran-
scription factor POU1F1 (previously termed PIT1; see be-
low)resultsinsynergisticactivationofthepromoterofthe
Prl gene and also, to a lesser extent, the Gh promoter (58,
59). PITX1 can also synergize with the transcription fac-
tors NEUROD1 and TBX19 (previously called TPIT) to
activate Pomc expression, whereas in gonadotrope cells it
activates Lhb expression in conjunction with the transcrip-
tion factors nuclear receptor 5A1 [NR5A1; also termed ste-
roidogenic factor 1 (SF1)] and Early growth response 1
(EGR1). PITX1 also appears to be essential for maintaining
theexpressionofGsuandtheGnRHreceptor(23,59–62),
anditisanessentialupstreamregulatorofLhx3(59,63,64).
Expression of Pitx1 is first detected in the anterior ecto-
derm at 8.0 dpc. By 9.5 dpc, Pitx1 is expressed throughout
the oral ectoderm and in Rathke’s pouch. Expression is
maintained throughout anterior pituitary development
in all hormone-producing cell types (58, 65). In the adult
pituitary, Pitx1 expression is highest in GSU-expressing
thyrotropes and gonadotropes and some POMC-produc-
ing cells, with lower levels in other hormone-producing
cell types (66). Mice with a homozygous disruption of
Pitx1 die before or shortly after birth, reflecting the pleio-
tropic functions of the protein during development, with
a small subset exhibiting embryonic lethality at 11.5 dpc.
Morphogenesis of the pituitary in Pitx1 null embryos ap-
pears normal. However, at birth an increase in the levels
ofActhtranscriptsandproteinwasnotedincorticotropes,
whereas the number of gonadotropes and thyrotropes, as
well as levels of LH and TSH, were greatly diminished
(67). The presence of the closely related transcription fac-
torPITX2inRathke’spouchcouldexplaintheabsenceof
early defects (see below).
4. Pitx2
PITX2exhibitsalargedegreeofsequenceidentitywith
PITX1 (68, 69) and is similarly capable of activating the
promotersofmostofthepituitaryhormonegenes(59,70,
71).ExpressionofPitx2isinitiatedintheoralectodermat
8.5 dpc and is maintained throughout development of
Rathke’s pouch and in the surrounding mesenchyme (68,
72).Itsexpressionismaintainedintheadultglandmainly
in thyrotropes and gonadotropes (64). It is expressed in nu-
merous endocrine cell lines in vitro, as is PITX1 (64, 68).
Homozygous loss of Pitx2 results in early embryonic le-
thality with a severe phenotype, consistent with the wide-
spread expression of this gene (73–76). In contrast to Pitx1,
pituitary development is severely affected in Pitx2 null em-
bryos. Rathke’s pouch undergoes initial specification, but
Hesx1 expression is not maintained and development of the
pouch is arrested by 12.5 dpc (76). Studies have shown that
activationoftheWNTsignalingpathwayorconstitutiveac-
tivation of -catenin can induce Pitx2 expression. In turn,
PITX2 controls genes such as cyclin D1 and Cyclin D2 that
regulatethecellcycle(77,78).Ithasthereforebeenproposed
that pituitary hypoplasia in Pitx2 null mice may result from
decreased cell proliferation (77). Another study shows how-
ever that lack of Pitx2 results in excessive cell death during
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survival rather than proliferation (64). Indeed, it could be
involved in both survival and proliferation.
TheexpressionpatternsofPitx1andPitx2overlapdur-
ing early pituitary development, suggesting a possible re-
dundancy as intimated above; indeed animals mutant in
both genes show a more severe phenotype. Expression of
Lhx3 is undetectable in these, whereas single mutants do
show Lhx3 expression. This supports the notion of some
functional redundancy between PITX1 and PITX2; how-
ever, the single mutant phenotypes show that early devel-
opmentismoredependentonPITX2thanonPITX1(64).
By creating a hypomorphic allele of Pitx2, Gage et al.
(76) were able to assess its role in later stages of pituitary
differentiation. Generation of an allelic series containing
different combinations of Pitx2 wild-type, hypomorphic,
and null alleles showed that reduced dosage of Pitx2 is
proportionaltotheextentofpituitaryhypoplasiaandcel-
lular differentiation (79). Examination of hypomorphic
Pitx2 homozygous embryos, which survive postnatally,
revealed that the gonadotrope lineage was most pro-
foundlyaffected.Numbersofdifferentiatedsomatotropes
and thyrotropes were also reduced in mice homozygous
for the hypomorphic allele; however, the corticotrope
population appeared unaffected, as judged by the normal
expression of Pomc (79). Finally, overexpression of Pitx2
inthegonadotropeandthyrotropelineagesunderthecon-
trol of GSU regulatory sequences results in exclusive ex-
pansion of the gonadotrope population (64). This speci-
ficity may rely on the requirement of PITX2 for the
expression of the genes encoding gonadotrope-specific
transcription factors GATA2, EGR1, and NR5A1 (SF1)
(79).Inconclusionbothfactorsareinvolvedinprogenitor
maintenance, or expansion, with a prominent role for
PITX2. Later on they are individually necessary within
specific endocrine cell populations.
The third member of this family, PITX3, which has a
major role in left-right asymmetry, has been implicated in
pituitary development in lower vertebrates, where it defines
an equivalence domain for the lens and anterior pituitary
placode(80).MutationsaffectingPITX3havebeenreported
inhumanpatientswithanteriorsegmentdysgenesisandcat-
aract, and loss of expression in the lens is associated with
aphakiainmice(81,82);however,becausethereiscurrently
little information pertaining to its role in pituitary develop-
ment in mammals, we will not discuss it further.
C. LIM homeodomain transcription factors
1. Isl1
ISL1 is a member of the LIM homeodomain family of
transcription factors, characterized by two tandemly re-
peated cysteine/histidine-rich LIM domains, involved in
protein-protein interactions between the N-terminal end
oftheproteinandtheDNA-bindinghomeodomain.Com-
binatorial expression of LIM transcription factors has
been shown to be important in different cell specification
events (83), and it is becoming clear that related proteins
and cofactors for LIM proteins interact to regulate target
genes in pituitary cells (84, 85).
ISL1 is the first LIM protein to be expressed during
pituitary development; initially detectable at 8.5 dpc
throughouttheoralectoderm,itbecomesrestrictedtothe
pouch at 9.5 dpc. Between 10.5 and 11.5 dpc, its expres-
sion is gradually restricted to the ventral portion of the
pouch, which will begin to express Cga and subsequently
Tshbbecausethecellsbecomerostraltipthyrotropesafter
12.5dpc(22).Thisdynamicexpressionpatternappearsto
be dictated by interactions with the surrounding tissues
(see below).
Homozygous loss of Isl1 results in developmental ar-
rest by 10 dpc, at which time the oral ectoderm of mutant
mice has invaginated, but pouch formation is blocked at
an early stage. This suggests that the gene is necessary for
pituitaryprogenitorcellproliferationand/ormaintenance
(86).Itsfunctionatlaterstageshasnotbeendescribed,and
to date no human mutations in ISL1 have been identified.
2. Lhx3
Lhx3 is expressed early during anterior pituitary devel-
opment, initially with strong uniform expression within
Rathke’s pouch at 9.5 dpc (87). Subsequently, although its
expression is maintained throughout the pouch, from 12.5
dpc it forms a gradient of expression with higher protein
levels dorsally (88–90). By 16.5 dpc, Lhx3 is present
throughout the pituitary, and expression persists into adult-
hood (89). Mice with a targeted homozygous disruption of
Lhx3 die shortly after birth and exhibit pituitary aplasia,
whereas heterozygous mice are normal. Although Rathke’s
pouch develops, its expansion is arrested in null embryos by
12.5 dpc (87). Moreover, whereas Hesx1 and Isl1 are ex-
pressednormallyat9.5dpcinthesemutants,theirexpression
fails to be maintained from 12.5 dpc (87, 90). Defects in cell




/pituitaries involves defects in the dif-
ferentiation of all endocrine cell types. Dorsoventral cell
specificationappearsimpaired,andthismay,inpart,bedue
to disrupted Notch signaling because Notch2 fails to be ex-
pressed in the mutants.
FailuretoactivatePou1f1(Pit1)resultsinapredictable
loss of lactotropes, somatotropes, and thyrotropes (87,
90) (see Section V). Gonadotropes also fail to fully differ-
entiate, probably due to the down-regulation of Foxl2 and
GSU.AsimilarlossofbothTBX19(TPIT)andNEUROD1
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intermediate lobe, down-regulation of Tbx19 expression
is consistent with the observed absence of melanotropes.
Therefore, LHX3 is required for early progenitor survival
aswellaslateendocrinecelldifferentiationevents,reflect-
ing its wide expression pattern both spatially and tempo-
rally. Its pleiotropic functions are reflected by its different
target genes: Fshb, Cga, Prl, Tshb, Gnrhr, and Pou1f1
(91–94) and partners including Pou1f1 and Isl1 (91, 95).
MutationsinLHX3havenowbeenidentifiedinanumber
of human pedigrees characterized by CPHD, a short stiff neck,
and variable sensorineural hearing loss (see Section VI).
3. Lhx4
Lhx4 is closely related to Lhx3 and is also expressed
throughout the invaginating Rathke’s pouch at 9.5 dpc.
Subsequently,however,theexpressionpatternsofthetwo
genes differ (89, 96, 97). Although Lhx3 is widely ex-
pressed and maintained throughout the developing pitu-
itary,Lhx4expressionistransient,becomingrestrictedto
thefutureanteriorlobeby12.5dpcandeventuallydown-
regulated at 15.5 dpc (89).
Homozygous Lhx4
/ mice die shortly after birth,
whereas heterozygous animals appear normal (89). As is
the case with Lhx3 null mice, loss of Lhx4 does not pre-
vent definitive pouch formation but results in the forma-





is a slight reduction in cell proliferation, the small size of
the anterior pituitary is clearly due to a wave of apoptosis
completedby14.5dpc(88).LHX4isalsorequiredforthe
proper expression of Lhx3, specifically during early pitu-
itary development. This may also involve another pitu-
itary-specific transcription factor, PROP1, because em-
bryoslackingbothLHX4andPROP1failtoexpressLhx3
at early stages of pituitary morphogenesis (88).
GenerationofmicewithvariouscombinationsofLhx3
and Lhx4 gene dosage using single and double knockouts
hasrevealedthatasinglewild-typealleleofeitherLhx3or
Lhx4 is sufficient for the formation of a definitive pouch
structure, and that homozygous loss of both genes does
not prevent formation of a rudimentary pouch at 9.5 dpc,
butthereisnoprogressionbeyondthisstage.Thisstrongly
suggests early functional redundancy when expression of
the two proteins overlaps (98). Later, however, normal
specification and terminal differentiation of the pituitary
cell types is entirely dependent on the presence of at least
one copy of Lhx3, not Lhx4, showing that functional re-
dundancy is temporally limited (98).
Heterozygous mutations within LHX4 have now been
described in a number of human patients with CPHD (see
Section VI).
D. SOX transcription factors
Sox2 together with Sox1 and Sox3 are all grouped into
the B1 subfamily of Sox genes (of which there are 20 in
miceandhumans)basedontheirextensivehomology.The
SOX proteins bind and bend DNA with their HMG do-
main; they can modulate gene activity as classical tran-
scription factors but, due to the nature of the acute bend
they induce in the DNA, they are also involved in the
assembly of transcriptional complexes (99–101). During
pituitary development, SOX2 is expressed in the early ec-
toderm and maintained throughout the pouch. Its expres-
sion is down-regulated as endocrine cell differentiation
proceeds.Expressionismaintainedintheprospectivepro-
genitor proliferative zone, around the Rathke’s pouch lu-
men, during embryogenesis but also in the mature gland
(17). It is also expressed in the ventral diencephalon (see
below).
Sox2
/ null embryos die shortly after implantation
and therefore provide no information about its role in the
pituitary (102). However, about one third of Sox2 het-
erozygous mice show perinatal lethality, and we have re-
cently shown that the remaining animals are affected by a
mild hypopituitarism (103). We also detected in a pro-
portion of heterozygous mutants a mild hypoplasia of the
anterior pituitary gland from Rathke’s pouch stages until
adulthood (K. Rizzoti, unpublished observations), which
couldunderliethehypopituitarism.SOX2couldtherefore
be required for the maintenance or proliferation of pitu-
itary progenitor cells in the embryo. It may also be in-
volved in the regulation of expression of Hesx1 (103,
104). Along with the size reduction, the embryonic pitu-
itaries of Sox2 mutants displayed abnormal bifurcations
resulting in the presence of extra clefts in the adult gland
(103). These may be caused indirectly by the reduction of
SOX2 in the overlying neuroepithelium (see below).
Sox2 expression is also seen in specific subpopulations
of hormone-negative cells in the postnatal and adult pi-
tuitary (17). Some of these line the cleft and are probably
direct descendents of the luminal cells lining Rathke’s
pouch; others are scattered in adjacent tissue of the ante-
rior pituitary. It has recently been shown that SOX2-pos-
itive cells, dissociated from adult pituitaries, are able to
form pituispheres in culture (17). These are free-floating
balls of cells derived clonally by proliferation of a single
cell. The majority of cells within the spheres retain Sox2
expression when grown in growth factors [epidermal
growth factor (EGF) and fibroblast growth factor (FGF)],
but they can be induced to differentiate by removing
growth factors and allowing the spheres to attach to a
substrate. They quite rapidly lose SOX2 and give rise to
endocrine-producing cells. All the endocrine cell types
found in the anterior lobe can be found (essentially at
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are kept in growth medium and dissociated into single
cells, these can give rise to secondary pituispheres, which
have similar properties to the primary spheres. Together
these data provide in vitro evidence for the presence of
self-renewing progenitor or stem cells, marked by Sox2
expression.Itisthereforepossiblethatatleastsomeofthe
SOX2-positive cells in the adult pituitary also represent
multipotent pituitary progenitor/stem cells. These could
play a role in pituitary plasticity when changing physio-
logical situations, such as lactation or pregnancy, lead to
changes in numbers and types of endocrine cells (17).
Lineage tracing studies will be necessary to show the
contributionofsuchadultstemprogenitorstonormalen-
docrinecellturnover.Asubsequentreportattemptedtodo
so, although this did not concern Sox2 expression (18).
Although the conclusions were in broad agreement with
the notion that there are stem/progenitor cells located in
the region of the cleft, additional methods are required to
prove this. Moreover, further work is required to show
whetherSOX2isimportantfortheidentityandproperties
ofthesecellsasstem/progenitorcellsasitisforotherstem
cells types, such as embryonic stem cells and neural stem
cells (102, 105).
De novo SOX2 mutations have now been identified in
a number of patients with eye defects such as anophthal-




atresia, and sensorineural hearing loss (see Section VI).
Unlikethemurinephenotype,wherehaploinsufficiencyis
associated with a generalized reduction in pituitary cell
numbers,inhumansthephenotypeconsistentlyappearsto
includehypogonadotropichypogonadism,whereasGHD
is rarer and other cell types do not seem to be affected.
E. WNT/-catenin and Notch signaling pathways
1. WNT/-catenin signaling
WNT signaling pathways are repeatedly involved dur-
ingembryogenesisandareimplicatedincellproliferation,
determination, and differentiation events and also in de-
terminingcellpolarity.WNTligandsactivatetheirsignal-
ing cascade by binding to a complex comprising Frizzled
receptors and LRP proteins (low density lipoprotein-re-
lated receptor). At least three alternative pathways can
then be activated: 1) a -catenin-dependent pathway that
affects transcriptional activity, usually through binding
TCF/LEF proteins, which can then function as transcrip-
tional activators; 2) the planar cell polarity pathway; and
3) a Ca
2-mediated pathway related to cell adhesion (for
review, see Ref. 106 and references therein).
A pathway involving signaling via WNT/Disheveled/
-cateninactivatestheexpressionofPitx2,promotingthe
proliferation of pituitary precursors (77). The identity of
the WNT ligand inducing this pathway is not known, but
the expression of several candidate ligands has been de-
tected within the developing gland (107–109). In partic-
ular, Wnt4 is expressed in the pouch from 9.5 dpc, and its
deletion results in pituitary hypoplasia (108, 110). How-
ever, the origin of this defect is not clear. It was originally
shown that GSU expression, in particular, was reduced
in Wnt4
/ embryonic pituitaries (110), whereas a more
recent report finds reduced POU1F1 (PIT1), but normal
levels of GSU (108). TCF4, a downstream effector of
WNT/-catenin signaling, is present in Rathke’s pouch
and also in the ventral diencephalon. Its deletion induces
the presence of abnormal bifurcations of the pouch, al-
though this may be due to its deletion in the overlying
CNS (see below). However, Tcf4 mutants also show
pituitary hyperplasia (111, 112), which could be ex-
plained by the expansion of Six6 expression in the
pouch at 11.5 dpc (113).
The phenotypes of WNT4 and TCF4 appear contra-
dictory, but in the absence of WNT signaling, TCFs ac-
tively repress transcription, so the two loss of function
mutations are not comparable. Nevertheless, these data
suggestthatintheabsenceofWNTligand,TCF4restricts
SIX6 expression to control progenitor cell proliferation;
but in the presence of WNT, proliferation is encouraged.
This may also reflect a more complex crosstalk of path-
ways controlled by different ligands secreted both by the
ventral diencephalon and within the pouch (107, 108).
Furthermore WNTs and -catenin can cooperate with
other signaling pathways, in particular the Notch signal-
ing pathway (106), and it may therefore not be surprising
to obtain different phenotypes when manipulating the li-
gandvs.eitherintermediatecentraleffectorslike-catenin
or specific downstream effectors.
2. Notch signaling
Notch proteins are transmembrane receptors display-
ing an extracellular domain made of epidermal growth
factor-likerepeatsandanintracellulardomaincomprising
Ankyrin-like repeats. Four Notch receptors are present
in mammals. Upon activation by ligands (in mammals,
Delta1, -2, -3, and -4; Jagged1 and -2), the intracellular
domain of Notch is released and translocates to the nu-
cleus where it activates transcription via its main effector,
the protein RBP-J/CSL. Among its transcriptional target
genes are members of the Hairy enhancer of Split (Hes)
andbHLHtranscriptionfactors(forreview,seeRef.106).
This signaling pathway mediates the process of lateral in-
hibitionwherecellswithingroupsaresingledouttoadopt
aparticularfate.Itisusediterativelyduringdevelopment,
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decisions.
During pituitary development, Notch2, Notch3,
Jagged1, and Hes1 are expressed at 9.5 dpc in the invag-
inating pouch. They are then quickly down-regulated
from the differentiating zone ventrally but maintained
dorsally around the lumen of Rathke‘s pouch (114, 115).
Notch signaling pathway components are expressed by
cells in the adult gland in the same locations that are pro-
posedtocontainprogenitor/stemcellsasthosementioned
above (see Section III.D) (116).
TogaininsightintoNotchsignalingfunction,Zhuetal.
(115) deleted Rbp-J exclusively in Rathke’s pouch, result-
ingintheprematuredifferentiationofcorticotropes.Such
a phenotype is also observed when a downstream effector
ofNotch,Hes1,isdeleted(117).Thislatterphenotypewas
correlated with decreased proliferation (115, 117); how-
ever one study also reported increased cell death (7). In
Rbp-J
/ embryos, Prop1, a direct target of RBP-J (115),
fails to be up-regulated at 12.5 dpc. As a consequence,
Pou1f1 (Pit1) fails to be expressed (see below). Therefore
Notch signaling could be required to prevent early (cor-
ticotrope) differentiation and maintain undifferentiated
progenitors fated for a later (POU1F1-dependent) fate. In
this way, Notch signaling would allow the generation of
different endocrine cell types by controlling the time and
therefore the context in which they differentiate.
IV. Regulation of Rathke’s Pouch Development
by the Ventral Diencephalon
Experimental manipulation of embryos from several spe-
cies, as well as Rathke’s pouch explant experiments in




cell types (22, 110, 118–123). Recently, however, careful
examination of the expression patterns of signaling mol-
ecules within the ventral diencephalon has revealed their
presence for longer than previously thought, raising ques-
tions about a prolonged influence of the developing in-




(also known as T/ebp, Ttf1, Titf1). This results in the loss
oftheventralforebrainandthecompleteabsenceofRath-
ke’spouch,althoughNkx2.1isnotexpressedinthelatter.
This confirmed a role for the ventral diencephalon in the
maintenance and survival of the pouch (125). It does not
provide the only influence, however, because the sur-
roundingmesenchymeisalsoinvolved(126)(seealsoSec-
tions IV.A and IV.B).
A. Bone morphogenetic proteins and fibroblast growth
factors: synergy and antagonism
1. Bmp4
Bone morphogenetic proteins (BMPs) belong to a fam-
ily of 20 secreted molecules, which bind to serine-threo-
nine receptor kinases that in turn transduce an intracel-
lularactivationcascade.SomemembersoftheBMPfamily
are involved in multiple events during embryogenesis.
BMP4 is the earliest signaling molecule known to be ex-
pressed in the prospective infundibulum, arising at 8.5
dpc,asRathke’spouchisfirstvisible;itismaintainedthere
until 14.5 dpc (22, 124).
Complete deletion of Bmp4 usually results in early em-
bryoniclethality(127);however,histologicalanalysisofa
few mice that survived to 10 dpc failed to show any sign
of pouch formation or even a thickened ectodermal pla-
code (86). In contrast, in Nkx2.1 null mutants where the
Bmp4 expression domain is initially present, a rudimen-
tary pouch forms but fails to enlarge by cell proliferation
(86). Moreover, ectopic expression of the BMP2/BMP4
antagonist noggin within the oral ectoderm and Rathke’s
pouch results in early arrest of pouch development at 10
dpc(110).AlsodeletionofthegeneencodingfortheBMP
receptor,Bmpr1a,inRathke’spouchat9.5dpcresultedin
an underdeveloped structure at 10.5 dpc (early lethality
preventedinvestigationsatlaterstages)(124).Incontrast,
noggin null embryos showed expanded domains of Bmp4
activity within the ventral diencephalon resulting in a
range of Rathke’s pouch phenotypes from an enlarged,
rostrally displaced pouch to induction of a second pouch
resulting in pituitary duplication (124). All these data im-
plicate BMP4 as the earliest secreted molecule required in
the ventral diencephalon for induction and maintenance
of Rathke’s pouch.
SeverallinesofevidenceshowthatexpressionofIsl1in
the developing anterior pituitary is regulated by BMP4
signaling from the ventral diencephalon. First, the timing
ofexpressionofIsl1throughoutRathke’spouchcoincides
with the maximum expression of Bmp4 at 9.5 dpc, which
declinesby11.5dpcasIsl1becomesdown-regulated.Ad-
ditionally, ectopic expression of Bmp4 within the pouch
expands the Isl1 expression domain within the anterior
lobe (110), whereas noggin null mice show ectopic ex-
pression of Isl1 in the mesenchyme adjacent to Rathke’s
pouch. Furthermore, loss of BMPR1A within Rathke’s
pouch prevents expression of Isl1 (124). Therefore regu-
lation of Isl1 expression could, at least partially, be re-
sponsible for the maintenance and survival effects of
BMP4 on Rathke’s pouch progenitor population.
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Members of the FGF family activate receptor tyrosine
kinases, and their extracellular association with heparan-
sulfate proteoglycans is crucial for their activity in multi-
ple processes during embryogenesis.
Three of the 23 members of this family (Fgf8, Fgf10,
and Fgf18) begin to be expressed in the infundibulum by
9.5 dpc, 24 h later than the onset of Bmp4 (22, 110, 123)
Transcripts from Fgfr2, encoding an FGF receptor, have
beendetectedinRathke’spouchadjacenttothedomainof
Fgf8 expression (86). This timing of expression corre-
sponds to the ability of the infundibulum to inhibit dif-
ferentiation dorsally, by down-regulating the expression
of Isl1 and thereby restricting it to ventral prospective
thyrotropes, and also to maintain proliferative progeni-
tors by inducing the expression of Lhx3 and Lhx4 in the
pouch. Indeed, treatment of pouch explants by Fgf8 in-
duced Lhx3 expression, whereas Isl1 expression was re-
stricted away from the source of the factor (22). At later
stages(16.5dpc),Lhx3expressionappearstobeindepen-
dent of FGFs (124). In contrast, treatment with a specific
FGF receptor antagonist, mimicking the loss of FGF sig-





) in the dorsal region along with sig-
nificantly reduced proliferation (128). Later, at around
11.5dpc,FGF8canrestrictcorticotropedifferentiationto
an intermediate zone of the pouch in between ventral thy-
rotropes and dorsal proliferative progenitors in contact
with the factor source (22). Moreover, early ectopic ex-
pression of Fgf8 under the control of the Cga (GSU)
promoterwithinRathke’spouchresultsinseveredysmor-
phogenesis and enlargement of the pituitary, with an ex-
pansionofPomc-expressingcells(corticotropesandmela-




lethality before gastrulation, precluding any study of its
role in Rathke’s pouch development (129), deletions of
Fgf10 or the gene encoding its receptor, Fgfr2IIIb, con-
firmed the proposed proliferative effect of FGFs on the
pouch. They both result in a poorly formed Rathke’s
pouch with widespread apoptosis resulting in absence of
thepituitary(130,131).Allthesedatashowaproliferative
roleforFGFsfromtheventraldiencephalonontoRathke’s
pouch after an initial induction by BMP4; however, an
additionalsignalingsourceisalsorequiredforcorrectpat-
terning of the pouch. Intriguingly, in humans, mutations
of FGF8 and the receptor FGFR1 appear to be associated
with Kallmann syndrome, resulting in isolated hypogo-
nadotrophic hypogonadism (132–134).
3. Bmp2
In contrast with Bmp4, Bmp2 is first expressed in the
ventral mesenchyme adjacent to Rathke’s pouch at 10.5
dpc along with Bmp7, but then gradually it is also found
throughoutthepouchitself,firstventrallythenexpanding
dorsally,from10.5to12.5dpc(22,124).Invitro,BMP2,
-4, or -7 is able to mimic the influence of ventral mesen-
chymeonpouchexplantsbyinducingIsl1expressionand
therefore favoring a ventral thyrotrope cell lineage (22).
Therefore, because BMP4 regulates early expression of
Isl1 throughout the pouch, BMP2 may subsequently be
responsible for its ventral maintenance. Maintenance of
Bmp2 expression under control of the Cga promoter re-
sultedinahyperplasticglandwithstrongexpansionofthe
expression domain of the transcription factor Gata2,
which is present in gonadotropes and thyrotropes but is
alsoinvolvedindeterminationofPOU1F1(PIT1)lineages
(see below) (110). However, as observed with FGF8,
down-regulation of BMP signaling is necessary for termi-
nal differentiation (110). In agreement with these data,
expression of a dominant-negative BMPR1A receptor (as
deletionofthegeneislethalearlyindevelopment)induced
the formation of a hypoplastic gland where POU1F1
(PIT1) cell lineages are essentially absent and the gonado-
trope population is reduced, whereas corticotropes and
intermediate lobe melanotropes are present (110).
In vitro, BMP signaling inhibits Pomc transcription
(135). Based on these results, it has been classically pro-
posedthatBMP2(andBMP7inventralmesenchyme)may
induce the proliferation and determination of ventral cell
types at least partially through regulation of Isl1 and
Gata2,whereasatthesamestagesFGFsinducedorsalcell
proliferation and restrict, along with BMPs, corticotrope
determination to an intermediate domain (summarized
in Fig. 2).
The field has therefore been stimulated by the notion,
derivedfromareasonableandconsistentinterpretationof
data obtained a while ago, that organizing gradients
across the developing pouch are crucial for spatial differ-
entiation signals. However, the presence of a dorsal FGF




consistent with a gradient model (124). Therefore, the
presence of several BMP inhibitors, including chordin,
noggin, NblI, and FstlI, within the infundibulum, the pi-
tuitary, and surrounding mesenchyme, as well as receptor
tyrosine kinase inhibitors of the Sprouty family in the
pouch, may all shape and modulate the range of activities
of BMP and FGF signaling in a rather more complex local
fashion. Moreover, they may interact with migrating
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thought, where the simple gradient model may not apply.
This suggests that simple gradients are not sufficient
and that proper morphogenesis of the pouch depends on
more interactions, including the program of cellular re-
sponsiveness interacting with concentration, and time of
exposure of individual opposing extracellular factors. Ul-
timately, however, it is the downstream signal transduc-
tionpathwaysthatintegrateandconvergethesesignalsto
a set of transcription factors that are critical for cell-fate
specification, and the challenge will be to identify what
these are, how they are controlled in temporal sequence
(both on and off) and how they function to activate spe-
cific differentiation pathways (110, 124, 136).
B. Sonic Hedgehog signaling
There are three mammalian hedgehog proteins—Sonic
Hedgehog (SHH), Indian Hedgehog (IHH), and Desert
Hedgehog (DHH)—that can act as morphogens during
development to elicit different cellular responses and in-
duce different cell fates. Again, these are thought to act
according to the distance from the source of hedgehog
(affectingthe“quantity”ofsignal),durationofthissignal,
andcompetenceofthereceivingcells.Thesepathwaysare
also involved for different purposes in adults. Hedgehog
ligands bind to and activate the transmembrane receptor
Patched, whereupon the Smoothened coreceptor is re-
leased, which activates transcription factors of the GLI
family that can either activate or repress transcription of
target genes.
Sonic Hedgehog (Shh) is expressed in the ventral dien-
cephalon, as well as throughout the oral ectoderm, from
which expression becomes excluded specifically within
Rathke’s pouch as soon as it appears (110, 123). Shh ex-
pression is subsequently lost within the oral epithelium at
12 dpc and within the ventral diencephalon by 14 dpc. In
contrast,thepatchedreceptorishighlyexpressedinRath-
ke’spouch(123),andthreemembersoftheGligenefamily
of transcription factors (Gli1, Gli2, and Gli3) are also
expressedintheventraldiencephalonandwithinRathke’s
pouch (137); therefore the developing gland is competent
to receive and respond to SHH signaling.
The effect of complete loss of SHH on pituitary devel-
opment in mice cannot be directly assessed because Shh
nullmiceexhibitcyclopiaandageneralizedlossofmidline
structures of the brain, including the regions expressing
Nkx2.1 (138). By expressing an antagonist of hedgehog
signaling, Hip, ectopically within the oral ectoderm and
Rathke’s pouch, Treier et al. (123) showed that pouch
development was arrested in transgenic embryos. A rudi-
mentary pouch was formed because BMP4 and FGF sig-
naling from the ventral diencephalon were not disrupted;
however, the pouch was severely hypoplastic. Lhx3 ex-
pression was gradually lost, except from the cells in con-
tact with the infundibulum, whereas Bmp2, Gata2, then
subsequently Pomc and Tsh, were not expressed.
FIG 2. Schematic representation of the developmental cascade of genes implicated in human pituitary development with particular reference to
pituitary cell differentiation.
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under the control of Cga regulatory sequences led to up-
regulation and maintenance of Bmp2 expression within
the developing pituitary at 17.5 dpc, resulting in overex-
pansion of the thyrotrope and gonadotrope cell types
(123). In contrast to a previous study where levels of in-
duced BMP2 were much higher (110), terminal differen-
tiation in the presence of BMP2 was observed (123). Ad-
ditionally, Lhx3 expression was slightly increased, and
pituitary volume was dramatically enhanced. Explant ex-
periments further showed that SHH along with FGF8 is
involved in Lhx3 induction and therefore progenitor pro-
liferation (123). These observations suggest that Shh sig-
naling in both the ventral diencephalon and the oral ec-
toderm is important for normal pituitary development,
regulating progenitor proliferation probably in part
through regulation of Bmp2 and Lhx3 expression. How-
ever, the spatial and temporal specificities of its action are





Clearly, while some actors, described here, are now
identified, their temporospatial roles and interactions re-
main to be determined.
C. WNT/-catenin signaling
During pituitary development, WNT signaling path-
ways are required both within the pouch (see above) and
in the ventral diencephalon. Wnt5a is the only member of
this extensive gene family known to be expressed in the
ventral diencephalon (110), and deletion of the gene in-
duces in particular a misshaping of the pouch with the
presence of extra bifurcations (139), similar to that ob-
served in Sox2 or Sox3 mutant embryos (see below). This
phenotype may be the consequence of a disruption of the
sharp ventral boundary of FGFs and BMP4 expression
domains in the infundibulum at 10.5 dpc, resulting in the
recruitment of a wider region of the oral ectoderm con-
tributing to Rathke’s pouch with consequent multiple bi-
furcations within it (112).
A similar phenotype as seen in Wnt5a
/ mutants is
also observed in Tcf4 null mice (111, 112), and the ab-
normalbifurcationsobservedaresimilarlymirroredbyan
expansion of FGF and BMP expression patterns in the
ventraldiencephalon(112).However,TCF4ispresentnot
only in the ventral diencephalon but also in Rathke’s
pouch itself, where it may control progenitor cell prolif-
eration. Therefore, in the ventral diencephalon, the func-
tion of WNT signaling might be more to control the in-
fundibular expression of FGFs and BMP4 to ensure
correct proper shaping and/or extent of the pouch. It
should also be borne in mind that the WNT signaling
pathway can interact with that of Notch, so phenotypes
may not solely be due to the effects of -catenin on LEF/
TCF-mediated transcription (106).
D. Sox3 and Sox2
Sox3, along with Sox2, is expressed throughout the
CNS with particularly high levels of expression noted in
theventraldiencephalon,includingtheinfundibulumand
presumptive hypothalamus (140, 141). Deletion of Sox3,
whichissituatedontheXchromosome,inducesavariable
phenotype mainly characterized by hypopituitarism and
craniofacialdefects(141–143).Rathke’spouchinSox3
y/
hemizygous embryos presents abnormal bifurcations that
persist in the adult gland as extra clefts. The protein is not
normally present in the pouch, but it is strongly expressed
in the ventral diencephalon, suggesting that impaired sig-
naling from the overlying mutant CNS could induce the
formation of additional bifurcations. Expansion of the
expression domains of BMP4 and FGF8 observed at 10.5
dpccouldexplainthese.Thisexpansionisprobablydueto
an abnormal morphology of the infundibulum, which is
lessevaginatedtowardthepouchandthereforeartificially
expanded ventrally. Additionally, a reduction in cell pro-
liferation was observed within this region (141).
In humans, both duplications and loss of function mu-
tations in the gene are associated with variable hypopitu-
itarism and variable learning deficits, often associated
with abnormal midline structures such as hypoplasia/
agenesis of the corpus callosum (see Section VIA).
SOX2 is also expressed in the ventral diencephalon,
andadditionalbifurcationshavealsobeenobservedinthe
pouches of Sox2
/ embryos, although at a lower fre-
quency (103). Although we cannot rule out a direct effect
ofareductionofSOX2inthepouch(seeabove)toexplain
theadditionalbifurcations,itispossiblethatSOX2isalso
involved in development of the ventral diencephalon. In
agreement with this, deletion of one copy of Sox2 on the
Sox3
y/backgroundresultsinamuchmoresevereventral
forebrain phenotype (K. Rizzoti, unpublished data).
As observed in Sox2 heterozygotes, the anterior lobe is
hypoplastic in Sox3
y/ animals, but the origin of this re-
duction is not known. By 15.5 dpc, expression of Sox3 is
initiated in the developing pituitary, in a small subset of
Pou1f1(Pit1)-positivecells,andlaterinsomelactotropes.
This expression is maintained in the adult (K. Rizzoti and
C. Galichet, unpublished data). However, the hypopitu-
itarism phenotype in the Sox3
y/ animals is unlikely to be
a consequence of the deletion of the gene in the pituitary
itselfbecausethephenotypeappearsonlyafterbirth,asthe
hypothalamus starts to control pituitary secretion. This
suggests that deletion of Sox3 in the CNS may have been
the cause of the hypopituitarism in the global mutants.
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Rathke’s pouch between Sox3 mutants and mutants in-
volving the WNT pathway suggests their interplay during
pituitary organogenesis. Studies in Xenopus have demon-
stratedthatXSOX3,aswellasXSOX17andXSOX17,
are capable of interacting with -catenin and repressing
theactivityofTCF-mediatedsignaling(144).Othermem-
bers of the SOXB1 family have also been reported to sup-
press -catenin-mediated TCF signaling (145). SOX2 has
also been reported to inhibit WNT/-catenin signaling in
murineosteoblasts,whereitrepressestheactivityofaTCF
responsive reporter, via an association of -catenin with
theC-terminaldomainofSOX2(146).Theseexperimen-
tal models suggest that interactions between the SOX
proteins and -catenin and the consequent effects on
-catenin target genes may be important for pituitary
development.
V. Factors Regulating Cellular Differentiation
The definitive Rathke’s pouch, formed by 11.5 dpc, ini-
tially contains undifferentiated proliferative progenitors.
Gradually, these will differentiate and give rise to the five
endocrine cell types present in the anterior pituitary. Nat-
urally occurring mutations, but also studies on the role of
specific genes during development, have led to the char-
acterization of several transcription factors involved dur-
ing endocrine differentiation. Regulated expression of
these,bothintimeandspace,isrequiredtoobtainthefull
setofendocrinecellsatbirth.Wewillnowdiscussthebest
studied/most representative among these factors.
A. Prop1
PROP1 is, like HESX1, a member of the paired-like
family of homeodomain transcription factors. It is ex-
pressed exclusively during pituitary development where,
in contrast to HESX1, data suggest it is capable of func-
tioningbothasatranscriptionalactivatorandrepressorin
a context-dependent manner (38, 147). Prop1 expression
isfirstapparentat10dpcwithinRathke’spouch,atastage
when Hesx1 is still present. Expression of Prop1 peaks at
12 dpc throughout the pouch and is then markedly de-
creased, being maintained until 15.5 dpc only in the peri-
lumenal area where progenitors are located (39, 147).
The Ames dwarf mouse (df) was found to harbor a
naturally occurring mutation in the homeodomain of
PROP1, lowering its DNA binding activity (39). In fact,
mice homozygous for a targeted deletion ofProp1 show a
nearly identical phenotype to the Ames mutation, so it is
moreorlessequivalenttoanullallele(148).df/dfmiceare
deficientinGH,prolactin(PRL),TSH,andgonadotropins
and exhibit severe proportional dwarfism, hypothyroid-
ism, and infertility (39, 149, 150). Moreover, no interme-
diate lobe differentiation marker is expressed, and vascu-
larization of the developing gland is abnormal (151).
Morphologically, the gland is clearly hypoplastic in
adults, whereas at 14.5 dpc, it appears enlarged and dys-
morphic. In fact, this is due to a failure of dorsal progen-
itors in the perilumenal area to relocate ventrally and dif-
ferentiate (152). Normally, these progenitors express
Notch2 from 12.5 dpc (116), and ventral relocalization is
accompanied by down-regulation of CyclinD2 (cell cycle
exit). However, in Prop1 mutants, dorsal cells fail to ex-
press Notch2, and CyclinD2 expression is down-regu-
latedwhilecellsarestillintheperilumenalarea(116,149,
152). Ward et al. (152) suggest that down-regulation of
NOTCH2 may be coupled with premature cell cycle exit
and defects in localization, in parallel with the role of
Notch in CNS precursors; however, another study
failed to show this down-regulation and suggested in-
stead that Notch signaling is essential for PROP1 main-
tenance (see above) (117). Finally, a late wave of apo-
ptosis and a reduction in proliferation in df/df mice
postnatally probably explain the subsequent pituitary
hypoplasia (114, 151, 152).
The switch of expression from the repressor HESX1 to
the activator PROP1 is an important step during devel-
opment of the gland because it is required for emergence
of both the POU1F1 (PIT1; GH, PRL, and TSH) and go-
nadotrope lineages (38). It has been known for some time
thatPROP1isdirectlyinvolvedintheactivationofPou1f1
(Pit1) expression (149, 153), but more recently, Olson et
al. (107) showed that in vitro PROP1 and -catenin
form a complex, along with other cofactors. Genetic ap-
proachescombinedwithchromatinimmunoprecipitation




result of the repressive actions of HESX1) to cell determi-
nation [activation of Pou1f1 (Pit1)] (107). Finally, over-
expressionofProp1underCgapromotercontrolresultsin
a delay inFshexpression leading to delayed puberty and
also an increased risk of pituitary adenomas. This high-
lights the importance of correct temporal regulation of
Prop1 expression (154, 155).
The gonadotropin deficiency observed in the Ames
dwarf (df) remains unexplained. In elegant studies that
unraveled the phenotype of the Ames dwarf, Bartke (156)
showed that male mice produced spermatozoa that were
motile, histologically normal, and capable of fertilizing
ova. However, most remained sterile although a few un-
treatedmaleswerefertileandsiredlitters.Administration
of T4 or GH singly or in combination resulted in fertility
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in sexual maturation in females, although fertility did not
ensue, possibly due to the absence of LH. Hence, the im-
paired fertility in Ames mice could be explained/exacer-
bated by concomitant untreated GHD and hypothyroid-
ism, although these interactions are complex because
thyroid hormone deficiency worsens GH deficiency, and
replacement of both is necessary to restore growth and
metabolism and for achieving functional sexual matura-
tion. Interestingly, the administration of T4 to GSU
/
mice led to gonadotrope hypertrophy, which had previ-
ously been lacking in these hypogonadal mice. Appropriate
thyroid function and timing may be required to establish
the sensitivity of gonadotropes to feedback regulation by
gonadal steroids (158).
In humans, PROP1 mutations are the most common
cause of CPHD, including GH, TSH, gonadotropin, and
evolving ACTH deficiencies. These are variable in onset
and phenotype and may be associated with a pituitary
massthatspontaneouslyinvolutestoresultinahypoplas-
tic anterior pituitary (see Section VI.B).
B. Pou1f1
POU1F1 (previously termed PIT1) is a member of the
POU homeodomain family of transcription factors char-
acterized by two highly conserved protein domains, a
POU-specificdomainandaPOU-DNAbindinghomeodo-
main. Pou1f1 (Pit1) is expressed relatively late during pi-
tuitary development, becoming detectable from 13.5 dpc
in prospective somatotrope, lactotrope, and thyrotrope
cells (159). It reaches maximum expression in differenti-
ating GH, PRL, and TSH cells by 16 dpc, persisting in
these into adulthood (20, 159). It is required for the pro-
ductionofGH,PRL,andTSH,respectively,aswellasfor
the expression of Ghrhr (160, 161). Recently, analysis of
Pouf1 (Pit1) regulatory regions has shown that its early
activation involves different enhancers, one of them
bound by the giant zinc finger protein ATBF1 (162).
Two naturally occurring recessive mouse mutants ini-
tiatedthedissectionofPOU1F1(PIT1)function.First,the
Snell dwarf (dw) mouse harbors a point mutation within
the POU homeodomain (p.W261C) affecting DNA bind-
ing. Second, the Jackson dwarf (dwJ) mouse fails to ex-
press Pou1f1 (Pit1) as a consequence of a chromosomal
rearrangement (163). Both strains exhibit an identical
phenotype comprising postnatal, but not embryonic, an-
terior pituitary hypoplasia and GH, TSH, and PRL defi-
ciencies (163). In dw/dw mice, expression of Pou1f1 is
normal until 18.5 dpc, at which time it is significantly
reduced, eventually becoming extinguished postnatally.
The presence of POU1F1 binding sites within its own reg-
ulatorysequencessuggeststhatPou1f1(Pit1)canregulate
itself (164, 165). The presence of normal GH, TSH, and
PRL populations in the embryo shows that POU1F1
(PIT1) is dispensable for their initial emergence but
required for their postnatal expansion; indeed, in
Pou1f1
/ (Pit1
/) pups, it is a reduction in prolifer-
ation along with some apoptosis that leads to hypopla-
sia (151). In postnatal endocrine cells, expansion is
known to be under hypothalamic control, but there are




notype is still unknown.
IthasbeenshownthatPOU1F1(PIT1)isabletoinhibit
the transcription factor GATA2 (see below) indepen-
dently of its DNA binding properties to prevent gonado-
trope fate, whereas in thyrotropes, the two act in synergy
to promote the thyrotrope fate (166). This may explain
how overexpression of Prop1, which activates POU1F1
(PIT1), delays gonadotrope differentiation (see above). In
somatotropes,thePOU1F1(PIT1)targetgeneMath3,en-
coding a bHLH transcription factor, allows terminal dif-
ferentiationandisrepressedbyNotchsignaling,probably
preventing premature differentiation (115). POU1F1
(PIT1)functionisthereforemorethan“promotingitsown
lineage”; it impacts on the regulation of other cell types
ensuring that the proper balance of endocrine cell types is
achieved.
POU1F1 (PIT1) is reported to regulate its target genes
bybindingtoresponseelementsoftheirpromoterregions
and recruiting coactivator proteins, such as the cAMP re-
sponse element-binding protein-binding protein (167)
and other transcription factors like LHX3 to the tran-
scriptional complex (168).
In humans, mutations in POU1F1 are associated with




GATA2 belongs to a family of six transcription factors
characterized by the presence of at least one N-terminal
transactivation domain and a zinc finger DNA binding
domain. It has dual functions as a stem cell maintenance
factor in some tissues (169), but also promotes differen-
tiationinothers(forreview,seeRef.170).Gata2startsto
be expressed at 10.5 dpc in the ventral Rathke’s pouch,
where it is induced by BMP2 (166) along with -GSU, the
commonsubunitofLH,FSH,andTSH.Itthereforemarks
prospective, then definitive, gonadotropes and thyro-
tropes; its expression is maintained in the adult (166).
GATA2 has been shown in vitro to activate the Cga pro-
moter(171)andalsotoinduceTshexpressioninsynergy
with POU1F1 (PIT1) (166, 172).
DeletionofGata2resultsinembryoniclethalityat10.5
dpc because of yolk sac hematopoiesis defects (173).
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of the molecule was expressed under control of Cga reg-
ulatory elements. As a consequence, gonadotropes were
lost and thyrotropes reduced, whereas the Pou1f1 (Pit1)
expression domain was expanded (166). In contrast, ec-
topic expression of Gata2 under control of the Pou1f1
(Pit1) promoter resulted in dorsal expansion of the gona-
dotrope population to the detriment of Pou1f1 (Pit1)-de-
pendent lineages (166). Therefore, GATA2 may promote
and be required for specification of the gonadotrope and
thyrotropelineages,respectively,inoppositionandinsyn-
ergy with POU1F1 (PIT1) (166).
Further evidence of the function of GATA2 in promot-
ing gonadotrope and thyrotrope fate has recently been
providedbyaspecificinactivationoftheproteininGSU-
positive cells. In these mutants, where more than 90% of
the GSU-positive cells inactivate GATA2, the TSH and
LH population is reduced in neonates, but only tran-
siently. However, in adult animals, levels of circulating
TSH and FSH stay low, and the function of gonadotropes
and thyrotropes is abnormal. The transient nature of the
reduction in endocrine populations could be due to the
observed up-regulation of the closely related GATA3
(174). The differences in phenotypes observed between
expression of a dominant negative and the deletion of the
gene may be explained by the wider range of action of the
dominantnegative,whichmayalsoinhibitothermembers
of the family such as GATA3, and possible residual
GATA2 function in the conditionally ablated mice (175).
However, both studies clearly highlight the requirement
for GATA2 in the differentiation of gonadotropes and




named steroidogenic factor-1, SF1) is an orphan nuclear
receptorinvolvedasatransactivatingfactorinsteroidhor-
monebiosynthesis.Phospholipidbindinghasbeenshown
to increase its transactivation activity, although it is un-
certain whether these should be considered as conven-
tional ligands (for review, see Ref. 176). NR5A1 (SF1) is
expressed throughout the adrenal and reproductive axes
during development and postnatal life, regulating several
genes involved in sex determination, reproduction, and
steroidogenesis, including in the hypothalamus and pitu-
itary those encoding the GnRH receptor, LH, FSH, and
GSU(61,177–179).Inthedevelopingpituitary,GATA2
is capable of inducing Nr5a1 (Sf1) expression in the de-
veloping gonadotropes, with initial onset of expression at
13.5 dpc; therefore, after the initiation of GSU expres-
sion but before that of LH and FSH (166, 180). It has
beenshowninvitrothatinteractionofNR5A1(SF1)with
the transcription factors EGR1 and PITX1 (61), and also
more recently with -catenin (181), is involved in activa-
tion of Lh.
Nr5a1 (Sf1) null mutant mice exhibit adrenal and go-
nadal agenesis, male-to-female sex reversal, ablation of
theventromedialhypothalamicnucleus,andselectiveloss
ofgonadotropin,GSU,andGnrhrexpression(180,182–
185). However, exogenous GnRH treatment at very high
doses in Nr5a1 (Sf1) null mice is capable of inducing go-
nadotropin expression, demonstrating that gonadotropes
are present and can respond to stimulation (185). Mice
with a conditional deletion of Nr5a1 (Sf1) specifically
within the pituitary (as a result of conditional ablation in
GSUexpressingcells)alsohavegonadalhypoplasiawith
adramaticdecreaseinpituitarygonadotropinexpression,
and fail to develop normal secondary sexual characteris-
tics, whereas the adrenal glands and hypothalamus are
unaffected.Alsointhesemice,supraphysiologicaldosesof
GnRHcanresultinLHexpression,suggestingthatinthe
absence of NR5A1 a cofactor, possibly EGR1, can alone
activate Lh (186). These data show that pituitary ex-
pressionofNr5a1(Sf1)isnecessaryforgonadotropemat-
uration, representing one of the functions of this factor in
reproductive axis development.
Mutations of NR5A1 in humans are associated with
46XY sex reversal with adrenal failure, 46XY gonadal
dysgenesis, and 46XX ovarian insufficiency and prema-
tureovarianfailure(187,188).Thedetaileddescriptionof
the role of this gene in human disease is beyond the scope
of this review.
E. Tbx19
TBX19 (previously referred to as TPIT) is a member of
the T-Box family of transcription factors comprising 17
membersinmouse.TheT-boxistheDNAbindingdomain
of these factors, and some of them also have a transacti-
vation domain. In the case of TBX19 (TPIT), transcrip-
tional activation requires association with the coactiva-
torssarcomavirus/p160,butitcanalsointeractwithother
partners (for review, see Ref. 189). Tbx19 (Tpit) is exclu-
sively expressed in the developing pituitary, first at 12.5
dpc in POMC-positive cells, then in corticotropes and
melanotropes, where it is maintained in the adult gland
(23).ItiscapableofdirectlyactivatingPomcexpressionin
association with PITX1 (23).
Tbx19 (Tpit) deletion in mice induces severe ACTH
and glucocorticoid deficiencies, in addition to adrenal hy-
poplasiaandpigmentationdefects.Inthepituitaryofthese
mice there is very little POMC expression, and the inter-
mediate lobe is hypoplastic. In the embryo, the transient
expressionofNeuroD1inprecorticotropesisnotaffected,
andpremelanotropesarealsopresent.Thereforebothcell
lineages are initially specified in normal numbers. This
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and maintenance of both populations (5). Interestingly,
the hypoplastic intermediate lobe of Tbx19
/ (Tpit
/)
embryos contains both gonadotropes and POU1F1-inde-
pendent thyrotropes (therefore similar to those arising
from the early transient populations), suggesting that
TBX19 (TPIT) may normally inhibit acquisition of these
fates. Indeed, when it is overexpressed, the number of
GSU-positivecellsinmiceisreduced.Tshexpressionis
normal, but the population of gonadotropin-expressing
cells is greatly reduced. Different functions of TBX19
(TPIT) may underline its ability to repress gonadotrope
fate.First,itisabletodirectlyrepressCga(GSU)expres-
sion in vitro; and second, there is a mutual antagonism
betweenTBX19(TPIT)andNR5A1(SF1),independentof
DNA binding activity (5). Therefore, TBX19 (TPIT) pro-
motes and is required for corticotrope and melanotrope
fate while actively repressing gonadotrope identity.
Mutations in TBX19 (TPIT) are the commonest cause
of isolated ACTH deficiency presenting in the neonatal
period in humans (see Section VI.C).
VI. Disorders of Pituitary Development
in Humans
In this section, we discuss pituitary development in hu-
mans. It is clear that useful knowledge has been gained
fromcomparinggenotype/phenotypeanalysesinmiceand
humans. In general, there are great similarities (Fig. 3 and
Table 6), although there are notable exceptions, so one
should remain cautious in extrapolating detailed mouse
phenotypestohumans.Incontrasttothemouse,thereare
obvious limitations in what can be directly investigated in
human pituitary development. Human studies are also
pronetoascertainmentorreferralbias,andoftencasesare
too rare to generalize with confidence about phenotypic
prevalence. What is less often appreciated is that many
mouse studies are light on phenotypic detail, particularly
postnatally,whichhamperscomparisonwithmosthuman
data, and that strain background effects in mice can also
have major effects on phenotypic penetrance.
Congenital hypopituitarism encompasses a group of
different etiological disorders. It may manifest as isolated
deficiency of a single pituitary hormone; for example
IGHD, ACTH deficiency, gonadotropin deficiency (hy-




nerve hypoplasia or midline forebrain abnormalities.
Clinicalfeaturesofhypopituitarismareoftenvariableand
may occur early in the neonatal period or later with
growthfailureorabnormalpubertaldevelopment.IGHD
is by far the most common endocrinopathy and may
present with growth failure with an incidence ranging
from 1 in 3,500 to 1 in 10,000 births (190–194). At the
more severe end of the spectrum, SOD is a rare congenital
anomaly with a prevalence of approximately 1 in 10,000
(195).Itisageneticallyandphenotypicallyheterogeneous
disordercharacterizedbyaclinicaltriadofmidlinefore-
brain abnormalities, optic nerve hypoplasia, and hy-
popituitarism. Each of these components can occur in
isolation or in combination. The majority of cases of hy-
popituitarism are idiopathic in origin; however, familial
inheritance, which may be either dominant or recessive,
accounts for between 5 and 30% of all cases (196). The
etiologyofmanycasesstillremainsunknownandislikely
to involve a combination of both genetic and environ-
mental factors. Both genetic and environmental factors
have been implicated in the etiology of SOD, for exam-
ple (195, 197). Environmental agents such as viral in-
fections, vascular or degenerative changes, and expo-
sure to alcohol or drugs have been implicated in the
FIG 3. Midline sagittal hematoxylin and eosin-stained sections
showing pituitary organogenesis during human embryonic
development. A, Midline sagittal section of a Carnegie stage (CS) 13
embryo (approximately 5 wk of development) showing the
invagination of the oral ectoderm to form Rathke’s pouch (arrow). B,
Sagittal section of CS14 embryo showing the developing Rathke’s
pouch (Rp) coming into contact with the overlying neuroectoderm. C,
Sagittal section of CS15 embryo showing the definitive Rathke’s pouch
becoming separated from the oral ectoderm (oe). D, Definitive
Rathke’s pouch (Rp) shown in sagittal section fully separated from the
oral ectoderm maintaining contact with the neural ectoderm of the
diencephalon (Di) at CS17. Scale bars: A and D, 300 m; B and C, 100
m. [Images were kindly provided courtesy of D. Gerrelli, Medical
Research Council-Wellcome Trust Developmental Biology Resource,
University College London Institute of Child Health, London, United
Kingdom.]
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monly in children born to younger mothers, and it clus-
tersingeographicalareaswithahighfrequencyofteen-
age pregnancies (195, 198, 199).
Several genes causing abnormal pituitary function
when mutated in the mouse have also been implicated in
humanpituitarydevelopmentbytheidentificationofmu-
tations in their human orthologs in patients with various
hypopituitary phenotypes. These can be broadly catego-
rized into three groups: 1) mutations in genes involved in
early development and patterning of the forebrain and
pituitary; these tend to result in syndromic forms of hy-
popituitarism in association with extrapituitary defects
affecting other tissues where they are expressed, most of-
ten the eyes, optic nerves, or midline forebrain structures;
2) genes that are involved at initial stages of pituitary cell
differentiationoftenresultinginCPHD;and3)mutations
in genes encoding specific hormone subunits or required
for specification of particular cell types giving rise to iso-
lated pituitary hormone deficiencies. This review will fo-
cus on the early developmental genes as well as those in-
volved in cellular differentiation.
A. Syndromic hypopituitarism: early developmental
genes
1. HESX1
The variable phenotype of midline forebrain defects,
ocular abnormalities, and pituitary dysplasia observed in
Hesx1 null mice is highly similar to that observed in hu-
manSOD.Consistentwiththisobservation,fivehomozy-
gous and eight heterozygous mutations have been identi-
fied in HESX1 (OMIM 601802) in a small proportion of
hypopituitary patients, although these have highly vari-
ablephenotypesandnoobviousphenotype-genotypecor-
relation. Dattani et al. (46) reported a homozygous mu-
tation at a highly conserved arginine residue of the
homeodomain (p.R160C) resulting in loss of DNA bind-
ing of the mutant protein, which was identified in two
siblings(borntoconsanguineousparents)whomanifested
a severe SOD phenotype with panhypopituitarism. MRI
revealed anterior pituitary hypoplasia, an ectopic or un-
descended posterior lobe, agenesis of the corpus callosum
with an absent septum pellucidum, and optic nerve hyp-
oplasiawithasmallopticchiasm(Fig.4B)(46,197,200).
A second homozygous mutation was identified in a girl
presenting with GH and gonadotropin deficiency, subse-
quently evolving to deficiencies of ACTH and TSH. She
had hypoplasia of the anterior pituitary and an unde-
scended posterior pituitary, but with normal optic nerves
and no midline forebrain defects. This mutation, a thre-
onine/isoleucinesubstitutionatresidue26(p.I26T),liesin
ahighlyconservedengrailedhomologydomainintheami-
no-terminal part of the protein that is crucial for tran-
scriptional repression. The mutation was shown to result
in partial loss of repressor function in vitro, in part due to
impaired interaction with the TLE1 corepressor (48). The
milder phenotype associated with the latter mutation was
supported by recent data in the mouse (47).
Two siblings from a third consanguineous family were
found to be recessive for an Alu-element insertion in exon
3o fHESX1, which contains the homeobox (201). Af-
fectedindividualshomozygousforthemutationhadapla-
sia of the anterior pituitary and undetectable anterior pi-
tuitary hormone levels, although the posterior pituitary
and infundibulum were normal. One sibling had unilat-
eral blindness as a result of coloboma of the right eye,
whereas the other had no ophthalmic abnormalities but
displayed a left-sided diaphragmatic hernia and aortic co-
arctation and died shortly after birth. Two additional pa-
tients with recessive HESX1 mutations and anterior pitu-
itaryaplasiaintheabsenceofaposteriorpituitaryoroptic
nerve malformation have also recently been reported.
Sequencing HESX1 in these unrelated individuals re-
vealed that one was homozygous for a 2-bp deletion
(c.449_450delAC) resulting in a frameshift, whereas the




To gain further insights into the molecular basis of im-
paired HESX1 function by the p.R160C and p.I26T mu-
tations, Sajedi et al. (47) recently generated mouse mu-
tants carrying these alleles. Mice homozygous for the
p.R160C mutation displayed pituitary and forebrain de-
fects identical to those observed in Hesx1 null embryos,
whereas those homozygous for the p.I26T allele showed
pituitary defects and ocular abnormalities comparable to
those of Hesx1 null mice, but no defects in the telenceph-
alon, suggesting that the p.I26T mutation yields a hypo-
morphic allele, whereas p.R160C effectively produces a
null allele; this could explain its more severe phenotype in
both mice and humans. The fact that the p.I26T mutant
protein retains DNA binding but has impaired transcrip-
tional repressor function due to its inability to interact
with TLE1 suggests that this particular protein-protein
interactionisabsolutelyrequiredfornormalpituitaryand
eye development. The p.R160C substitution yields a pro-
teinwithnoDNAbindingpropertiesbutisabletorepress
transcription,indicatingthenecessityofHESX1:DNAin-
teractions for normal HESX1 function during develop-
ment. The expression pattern of HESX1 in human em-
bryos parallels that of other vertebrates, suggesting a
conserved evolutionary role in forebrain, eye, and pitu-
itarydevelopment(47).Additionally,thesedataaswellas
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that the pituitary gland is most sensitive to reductions in
HESX1 dosage, followed by the eyes and then the fore-
brain. This would appear to be the case in both humans
and mice (45, 47). Eight additional heterozygous muta-
tions of HESX1 have been identified in individuals with
various degrees of hypopituitarism and SOD
(Table 1). In general, these heterozygous
HESX1 mutations are associated with milder
phenotypes, and haplotype analysis in familial
cases has revealed that such mutations are
associated with incomplete penetrance, with
some affected individuals inheriting the muta-
tion from an apparently unaffected parent.
This raises the possibility that such heterozy-
gousmutationsarenotactingindependentlyto
causediseaseandthataffectedindividualsmay
harbor additional mutations in HESX1 (e.g.,
promoter/enhancer regions) or in other gene
products interacting with HESX1.
We have screened approximately 850 pa-
tients for mutations in HESX1 including more
than300withSOD;410withisolatedpituitary
dysfunction,opticnervehypoplasia,ormidline
neurological abnormalities; and 126 patients
with familial inheritance of the condition. The
overallincidenceofcodingregionmutationsin
HESX1 within this cohort is approximately
1%, showing that mutations in HESX1 are a
rare cause of hypopituitarism and SOD (199).
It is possible that homozygous mutations in
HESX1 result in early embryonic lethality and
that the few patients identified with HESX1
mutations represent the minority of surviving
individuals. If so, it follows that there is a
greaterlikelihoodofidentifyingmutationsin
genes that are not associated with other ma-
jor embryonic defects in surviving patients
with CPHD.
2. PITX2
Mutations in PITX2 in humans are associ-
ated with Axenfeld Rieger syndrome (OMIM
601542), a genetically and phenotypically het-
erogeneous disorder characterized by malfor-
mation of the anterior segment of the eye, den-
tal hypoplasia, a protuberant umbilicus, and
brainabnormalities(72).ReducedGHconcen-
trations and a small sella turcica, probably re-
flecting pituitary hypoplasia, have been noted
in some patients (203), suggesting a role for
PITX2 in pituitary development and hypopi-




been associated with bilateral anophthalmia or severe mi-
crophthalmia. Additionally, the phenotype of hypopitu-
FIG 4. A, Midsagittal MRI scan of the head of a normal child. Note the well-formed
corpus callosum (CC), the optic chiasm (OC), and the posterior pituitary (PP), which
appears as a bright spot within the sella turcica. B, Sagittal MRI scan of two siblings
with a homozygous p.R160C mutation in HESX1. In the first sibling (i) the splenium
of the corpus callosum is more hypoplastic than the rest of the structure and the
posterior pituitary is partially descended as compared with the other sibling (ii) who
has a severely hypoplastic corpus callosum, ectopic posterior pituitary, and lack of
visible pituitary stalk (PS). C, Coronal and sagittal MRI scans from one patient [panels
(i) and (ii)] and sagittal scan from a second patient (iii) with SOX3 duplication
showing anterior pituitary (AP) hypoplasia, partial hypoplasia of the infundibulum (I)
in the first patient, which is completely absent in the second, and an ectopic
posterior pituitary which is more severe in patient 2. D, MRI scan from patients with
SOX2 mutations. Sagittal section from patient with c60insG mutation showing
anterior pituitary (ap) hypoplasia with normal posterior pituitary (pp) and
infundibulum (i) and a hypothalamic hamartoma (h). E, Sagittal MRI scan in patient
with compound heterozygosity for p.E230K and p.R172Q mutations in POU1F1,
showing hypoplasia of the anterior pituitary gland with a normal posterior pituitary
and infundibulum. F, Sequential MRI scanning of a patient with a 13-bp deletion
(c.112_124del13) in PROP1 reveals waxing and waning of a pituitary mass (arrow);
(i) on initial presentation, (ii) after 4 months, (iii) after 12 months, and (iv) 21 months
after initial MRI. [Panels A and B were derived from Brickman et al. (200); panel C
was derived from Woods et al. (220) and reproduced with permission from Elsevier
(University of Chicago Press); panel D was derived from Kelberman, et al. (103) and
reproduced with permission from the American Society for Clinical Investigation.
Panels E (copyright 2005, The Endocrine Society) and F, derived from Turton et al.
(Refs. 274 and 250, respectively), were reproduced with permission.]
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gonadotropin deficiency (hypogonadotropic hypogonad-
ism) with genital abnormalities in males is present in all
cases where neuroimaging and endocrine investigations
have been performed to date (103, 104, 204, 205). Fore-
braindefectsreportedinsomepatientsincludehypoplasia
of the corpus callosum, hypothalamic hamartoma, and
hippocampal malformation (Fig. 4D) (103, 206), associ-
ated with additional abnormalities including esophageal
atresia, sensorineural hearing loss, and learning difficul-
ties. To date, 22 de novo intragenic heterozygous muta-
tions have been identified in 27 patients, including eight
nonsense, 10 frameshift, and three missense mutations
(103, 204, 205, 207–212). Additionally, seven de novo
heterozygous deletions of the entire gene and one case of
a partial 3 deletion have been reported (204, 205, 212,
213), as well as three heterozygous nonsynonymous
changesidentifiedinindividualswhoinheritedthevariant
from a clinically unaffected parent (103, 214). SOX2 ge-
netic variation is catalogued online (see http://lsdb.hgu.
mrc.ac.uk/home.php?select_dbSOX2). GHD has been
described in some patients (103), and many patients with
SOX2 mutations manifest hypogonadotropic hypogo-
nadism (103, 104, 210), which has obvious implications
for their clinical management. Continued endocrine fol-
low-up of individuals with SOX2 mutations and timely
diagnosisandtreatmentofGHandsexsteroiddeficiencies
would help prevent their associated long-term morbidities.
It is of interest to note that SOX2 expression is not
uniforminthedevelopinghypothalamusinhumans(104),
suggesting that haploinsufficiency for SOX2 may affect
onlycertainpopulationsofglia,neuroendocrineneurons,
their progenitors, or their afferent inputs. The report of a
patient with isolated hypogonadotropic hypogonadism
without pituitary hypoplasia on imaging (210) suggests
that SOX2 might be involved independently at multiple
levels during the development of the hypothalamo-pitu-
itary-gonadal axis, including the neural processes neces-
sary for establishing or maintaining the population of
GnRH neurons in the hypothalamus, their migration,
and/or formation of an appropriate terminal field in the
median eminence. These could be additional to the more
direct involvement of SOX2 in Rathke’s pouch morpho-
genesis. Because mice with haploinsufficiency of Sox2
show more generalized pituitary deficits, the apparent se-
lectivity for SOX2 mutations impairing primarily the go-
nadotrope axis in human subjects is intriguing and unex-
plained, and it is a reminder that phenotypic details differ
significantly between human and mouse.
SOX2 shows overlapping domains of expression with
LHX3 and HESX1 within Rathke’s pouch and the devel-
oping anterior lobe during human embryonic develop-
ment (47, 104, 215, 216). Moreover, SOX2 can bind to
sequences within the proximal promoters of both genes
andactivatetranscriptioninvitro,suggestingthatitmight
be a regulator of LHX3 and/or HESX1 during pituitary
development. SOX2 is also capable of repressing -cate-
nin mediated transcriptional activation in vitro. Muta-
tions that result in a truncated protein lose this inhibitory
activity, which is mediated by the carboxyl-terminal do-
TABLE 1. Mutations identified in the HESX1 gene in patients with SOD and hypopituitarism
Mutation Inheritance Endocrine phenotype Neuroradiological findings Ref.
p.Q6H (2 reports) Dominant GH, TSH, LH, FSH deficiency; GH
deficiency, evolving TSH, ACTH
deficiency
AP hypoplasia, ectopic PP 49, 295
p.I26T Recessive GH, LH, FSH deficiency; evolving
ACTH, TSH deficiency
AP hypoplasia, ectopic PP, normal ON 48
c.306_307insAG Dominant GH, LH, FSH deficiency;
hypothyroidism
AP hypoplasia, ON hypoplasia 296
p.Q117P Dominant GH, TSH, ACTH, LH, FSH deficiency AP hypoplasia, ectopic PP 297
c.357  2TC Recessive GH, TSH, ACTH, PRL deficiency AP aplasia, normal PP, normal ON 202
Alu insertion (exon 3) Recessive Panhypopituitarism AP aplasia, hypoplastic sella, normal PP and
infundibulum
201
p.E149K Dominant GH deficiency AP hypoplasia, ectopic PP, infundibular
hypoplasia
199
c.449_450delCA Recessive GH, TSH, ACTH deficiency AP aplasia, normal PP, normal ON, thin CC,
hydrocephalus
202
p.R160C Recessive GH, TSH, ACTH, LH, FSH deficiency AP hypoplasia, ectopic PP, ON hypoplasia, ACC 46
p.S170L Dominant GH deficiency Normal AP, ON hypoplasia, ectopic PP, partial
ACC
49
p.K176T Dominant GH deficiency, evolving ACTH, TSH
deficiency
Ectopic PP 297
g.1684delG Dominant GH deficiency AP hypoplasia, ON hypoplasia, ACC, absent PP
bright spot
298
p.T181A Dominant GH deficiency AP hypoplasia, normal ON, absent PP bright spot 49
AP, Anterior pituitary; PP, posterior pituitary; ON, optic nerve; (A)CC, (agenesis of the) corpus callosum.
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abilitytobindDNA(104,146).Disruptionofinteractions
with-cateninandtheconsequenteffectsonregulationof
-catenin target genes may also be one mechanism by
which loss-of-function mutations in SOX2 can result in
abnormal pituitary morphogenesis.
4. SOX3
A number of pedigrees have been described with X-
linked hypopituitarism and mental retardation, mapping
involving duplications of Xq26–27 encompassing SOX3
(OMIM 313430) (217–219), with the smallest described
duplicationtodatebeingapproximately690Kb(220).Of
the three annotated genes in this interval, only Sox3 was
expressedinthemurineinfundibulum.Thephenotypesof
affected males with X-linked hypopituitarism involving
duplications within this region are variable. All affected
malesmanifestGHdeficiencyassociatedwithanteriorpi-
tuitary and infundibular hypoplasia with an undescended
posterior pituitary and abnormalities of the corpus callo-
sum (218). Some individuals are also deficient in ACTH,
TSH,orgonadotropins,andpanhypopituitarismhasbeen
documented(219),withvaryingdegreesofdevelopmental
delay or mental retardation.
FurtherimplicationofSOX3inX-linkedhypopituitar-
ism came from the identification of patients harboring an
expansion of one of the polyalanine tracts within the gene
(220,221).Laumonnieretal.(221)identifiedanin-frame
duplicationof33bpoccurringbetweennucleotides711to
743 and cosegregating in affected males in a large family
withX-linkedmentalretardationandGHdeficiency.This
duplication encodes an additional 11 alanine residues,
predicts an expansion of this polyalanine tract from 15 to
26residues,andwasassociatedwithaphenotypeofshort
stature,IGHD,andmentalretardation,withfacialanom-
alies in some, but not all, patients. A second expansion of
sevenalanineresidueswithinthesametracthasbeeniden-
tified in three siblings of a consanguineous pedigree pre-
senting with profound and complete panhypopituitarism
in association with anterior pituitary hypoplasia, an ab-
sent or hypoplastic infundibulum, and an ectopic/unde-
scended posterior pituitary (Fig. 4C) (220). Interestingly,
there was no evidence of mental retardation or craniofa-
cialdysmorphismintheseindividuals.Adeletionresulting
in contraction of the same polyalanine repeat by nine res-
idues has also been reported in two brothers with mental
retardation; however, the significance of this finding re-
mains unknown because functional studies have not been
performed and the deletion was also present in the mater-
nal grandfather of the patients who was clinically unaf-
fected (221).
Consistent with the presence of the SOX3 locus on the
X chromosome, all patients described to date are male,
withfemalecarriersappearingclinicallyunaffected.How-
ever, no mutations involving SOX3 have been found in
patients with sex reversal, gonadal dysgenesis, or infertil-
ity (222, 223). It is striking that patients presenting with
duplicationsinvolvingSOX3,orloss-of-functionpolyala-
nine tract expansion mutations, show essentially similar
phenotypes, comprised of infundibular hypoplasia and
variable hypopituitarism. This suggests that the dosage of
SOX3 is quite critical for normal hypothalamopituitary
development. Given the observation that Sox3 is not nor-
mally expressed in Rathke’s pouch in the mouse, our cur-
rent view is that morphological defects of the anterior
pituitarymightbesecondarytodisruptionofinfundibular
development and signals thereof.
5. LHX3
Eight homozygous mutations in LHX3 (OMIM
600577) have been identified in 13 patients from eight
unrelated consanguineous families, in addition to a single
patient who was found to be compound heterozygous for
two missense mutations within the gene (Table 2). These
patients usually present with a multiple anterior pituitary
hormone deficit, with sparing of ACTH in the majority of
cases, although patients with ACTH deficiency have also
recently been described (216). Pituitary morphology is
variable between patients with LHX3 mutations: most
patients have a hypoplastic anterior pituitary with a nor-
mal posterior pituitary and midline structures (216, 224,
225); conversely, an enlarged anterior pituitary has also
been reported in a patient that was not evident in a pre-
vious MRI scan performed 10 yr earlier (224). Addition-
ally, a patient with a hypointense lesion in the anterior
pituitary consistent with a microadenoma has also been
described (226).
The majority of patients with LHX3 mutations re-
ported to date have also exhibited a short rigid cervical
spine with limited neck rotation and trunk movement.
Again, the skeletal phenotypes can vary, and a single pa-
tient with normal neck rotation and no other syndromic
features has been reported (225). Analysis of LHX3 ex-
pression during human development shows a pattern of
expression in the developing embryonic pituitary highly
similar to that observed in the mouse. Expression is de-
tected within Rathke’s pouch at 5 wk of development and
later in the anterior and intermediate region of the pitu-
itary,butnotintheposteriorlobe.ExpressionofLHX3is
also observed in specific regions of the spinal cord corre-
sponding to interneuron and motor neuron populations
(215). The underlying mechanism of the vertebral and
skeletal defects in patients with LHX3 mutations is un-
clear because expression is not detected in the sclerotome
or myotome, the tissues giving rise to the vertebrae and
skeletal muscle (Ref. 215, and our unpublished observa-
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notype of sensorineural deafness in association with ho-
mozygous loss of LHX3. The severity of hearing loss is
also highly variable and can range from profound to very
mild and may be missed in some cases (216). A direct role
may be implicated here because LHX3 is expressed in
specific regions of the inner ear in a pattern highly con-
served between humans and mice, and it is likely to have
a role in cochlea hair cell development (216, 227–229).
Most missense mutations identified in patients have
diminished capacity to activate transcription of the pro-
moters of several potential LHX3 target genes including
CGA, PRL, FSHB, TSHB, and POU1F1 (230, 231).
Frameshift mutations or deletions of several exons or the
entire gene have also been reported and are likely to rep-
resent null alleles as a result of premature protein trunca-
tion or nonsense-mediated degradation. The results sug-
gest that whereas complete lack of LHX3 results in
pathogenesis, a single functional copy may be sufficient
for normal pituitary development.
6. LHX4
To date, four separate reports have described six het-
erozygous mutations within LHX4 (OMIM 602146; Ta-
ble 3), with all patients exhibiting GH deficiency and as-
sociatedshortstatureonpresentation,againwithvariable
additional endocrine deficits and extrapituitary abnor-
malities. A heterozygous intronic mutation that abol-
ishesnormalsplicingofLHX4wasinitiallyreportedby
Machinis et al. (232) in a three-generation family segre-
gating in a dominant and fully penetrant manner. The
probands presented with short stature and were found to
beGH,TSH,andACTHdeficient,withanteriorpituitary
hypoplasia, an undescended posterior pituitary, and ab-
TABLE 2. Mutations identified in LHX3 in patients with CPHD and associated extrapituitary phenotypes
Mutation Endocrine phenotype Associated abnormalities Deafness phenotype Ref.




Elevated and anteverted shoulders,
restriction of cervical spine
rotation. No vertebral
malformation.




23-bp deletion GH, TSH, PRL, LH, FSH deficiency.
Enlargement of anterior
pituitary. Growth retardation.











configuration of cervical spine.





p.A210V (2 patients) GH, TSH, PRL, LH, FSH deficiency.
Enlarged anterior pituitary.
Growth retardation.
Short neck, elevated shoulders,
limited neck rotation, loss of




p.E173X GH, TSH, PRL, LH, FSH deficiency.
Anterior pituitary hypoplasia.





p.W224X GH, TSH, PRL, LH, FSH deficiency.
Growth retardation.
No syndromic features, normal
neck rotation.
Not described. 225
LHX3 gene deletion GH, TSH, PRL, LH, FSH deficiency.
Anterior pituitary hypoplasia.
Short neck with limited rotation,



















p.K50X GH, TSH, PRL, LH, FSH, ACTH
deficiency. Anterior pituitary
hypoplasia.
Short stiff neck, skeletal dysplasia.





mutation in intron 3
(c.455–2AG)
(6 patients)
GH, TSH, PRL, LH, FSH deficiency.
Aplastic/hypoplastic/cystic
anterior pituitary.
Short neck with restricted rotation.
Hypoglycemia, neonatal
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members presented with short stature associated with
IGHD and a normal posterior pituitary. Additional man-
ifestations included a poorly formed sella turcica and
pointed cerebellar tonsils. Subsequent follow-up revealed
that the male patient developed gonadotropin deficiency
at the age of 18, whereas his younger sister began spon-
taneous puberty (233). A second, de novo mutation, pro-
ducing a p.P366T substitution, was associated with a
more severe panhypopituitary phenotype. MRI demon-
strated a hypoplastic anterior pituitary, an undescended
posterior lobe, a poorly developed sella turcica, Chiari
malformation, and respiratory distress syndrome. Func-
tional studies confirming the pathogenic nature of this
mutation on the resultant protein were not performed
(234); however, the mutation was absent in both unaf-
fected parents, and the similarity in phenotype is consis-
tent with other patients harboring mutations demon-
strated to disrupt LHX4 function in vitro.
In a screen of 253 patients, Pfaeffle et al. (235) identi-
fied an additional three heterozygous missense muta-
tions—one occurring between the two LIM domains of
the protein (p.R84C) and two within the homeodomain
(p.L190R, p.A210P). The p.A210P mutation was identi-
fied in two female siblings presenting with short stature
and GH deficiency; MRI showed that both had a hypo-
plastic anterior lobe with cystic lesions but a eutopic
posterior pituitary. One sister had a more severe hy-
popituitaryphenotypewithadditionalTSH,ACTH,and
gonadotropin deficiencies, whereas the other had only
partial TSH deficiency. The mutation was inherited from
their father who had short stature and low GH, but no
evidenceofotherhormonedeficiencies(235).Thep.R84C
mutationwasidentifiedinasinglemalepatientpresenting




latter mutations had a small anterior pituitary and an un-
descended posterior pituitary on imaging, with no abnor-
malities in other regions of the brain. More recently, two
brothers have been described with a single base insertion
in exon 3 (c.293_294insC) resulting in a frameshift after
codon 99. Both siblings presented with GH and TSH de-
ficiencies with pituitary hypoplasia and a poorly devel-
oped sella turcica. The youngest brother also had a hyp-
oplastic corpus callosum and an undescended posterior
pituitary. Their father, who also harbored the mutation,
was GH deficient and had experienced delayed puberty
(233). The same genetic screen also identified two other
nonsynonymous variants (p.T90M and p.G370S); how-
ever, these changes did not alter LHX4 function in vitro
and may represent rare neutral variation.
Functional in vitro analyses of mutant LHX4 proteins
showedthattheyeitherfailtobindDNAorshowreduced
transactivation properties at the promoters of potential
LHX4 target genes including POU1F1, CGA, and TSHB
(233, 235, 236). This could account for LHX4 haploin-
sufficiency leading to GH, TSH, and gonadotropin defi-
ciencies. The additional brain malformations suggest that
LHX4 may be involved in the coordination of brain de-
velopment and skull shaping. It is interesting to note that
Lhx4
/ heterozygous mice display no observable phe-
notype, suggesting a difference in the requirement of
LHX4 dosage between the two species.
7. OTX2
Mutations in OTX2 (OMIM 600037) have been im-
plicated in the etiology of 2–3% of anophthalmia/mi-
crophthalmia syndromes in humans (237–239). To date,
two complete deletions and 12 heterozygous intragenic
mutations (of which six have been shown to be associated
with functional compromise) have been associated with
severe ocular and CNS phenotypes, including develop-
mental delay and seizures. The association of deletions of
14q22–23 (which also includes the candidate genes
BMP4, RTN1, SIX6, SIX1, and SIX4) with anophthal-
mia, hypopituitarism, and ear abnormalities (240) led to
the investigation of the role of OTX2 in hypothalamo-
pituitary development. A heterozygous de novo 2-bp in-
TABLE 3. Reported mutations in the LHX4 gene
Mutation Associated endocrine phenotype Neuroradiological findings Ref.
c.607–1GC GH deficiency, variable TSH, ACTH, gonadotropin
deficiency
AP hypoplasia, normal PP or undescended PP with
absent pituitary stalk, poorly formed sella turcica,
pointed cerebellar tonsils
232
p.P366T Panhypopituitarism AP hypoplasia, undescended PP, poorly developed
sella turcica, Chiari malformation
234
p.R84C GH, TSH, evolving gonadotropin deficiency AP hypoplasia, ectopic PP 235
p.L190R GH, TSH, ACTH deficiency AP hypoplasia, undescended PP 235
p.A210P GH deficiency, variable TSH, ACTH, gonadotropin
deficiency
Hypoplastic AP, normal PP 235
c.293_294insC GH deficiency, variable TSH, gonadotropin deficiency AP hypoplasia, variable undescended PP 233
AP, Anterior pituitary; PP, posterior pituitary.
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tified inaJapanese patient with bilateral anophthalmia and
panhypopituitarism associated with a small anterior pitu-
itary gland, an ectopic/undescended posterior pituitary, and
an absent infundibulum with a Chiari malformation (241).
The mutation generates a protein lacking the C-terminal
transactivationdomain,whichfailedtoactivatethepromot-
ersofHESX1andPOU1F1ascomparedwiththewild-type
protein. No dominant-negative activity was observed.
A de novo heterozygous frameshift mutation
(c.402insC) was identified in a Japanese female with bi-
lateralanophthalmiainassociationwithshortstatureand
partial GHD with a normal anterior pituitary gland on
MRI (242). The mutation resulted in a truncated protein
that was associated with reduced transactivation at the
IRBP, POU1F1, and HESX1 promoters. A further het-
erozygous point mutation (p.N233S) in the C-terminal
transactivation domain was identified in two unrelated
children with CPHD who presented with neonatal hypo-
glycemia (243). The first patient had a small anterior pi-
tuitary associated with an undescended/ectopic posterior
pituitary and an absent or severely hypoplastic infundib-
ulum, whereas the second patient had a hypoplastic an-
terior pituitary gland. The mutant p.N233S protein (243)
was able to bind to a consensus OTX2 binding sequence
but showed reduced transcriptional activation properties
compared with wild-type OTX2. Furthermore, the mu-
tant protein acts as a dominant-negative inhibitor of the
HESX1 promoter in vitro, suggesting that the hypopitu-
itaryphenotypesofthesepatientsmaybeduetodisrupted
expression of HESX1 (243). The OTX2 gene consists of
three exons that encode a 297-aa protein that contains a
homeodomain and a proline, serine, threonine-rich C-
terminal region that encompasses a highly conserved
SIWSPA peptide sequence and a tandemly repeated OTX
tail, and is required for anterior neural plate induction.
BecauseitappearstoregulatetheexpressionofHESX1,it
is possible that mutations in the protein compromise the
developmentoftheforebrainandventraldiencephalon,in
addition to any direct effect within Rathke’s pouch.
8. GLI2
Recently, the Sonic Hedgehog (SHH) signaling path-
way has been implicated in more complex disorders of
pituitary development. Mutations within SHH (OMIM
600725) are associated with holoprosencephaly (244).
Three members of the Gli gene family of transcription
factors have been implicated in the mediation of SHH
signals, and heterozygous loss of function mutations
withintheGLI2gene(OMIM165230)havebeenidentified
in patients with holoprosencephaly (245). Phenotypic pen-
etrance was variable, with the disorder transmitted through
aparentcarryingthemutationbutshowingnoobviousphe-
notype in one family. In all affected individuals with GLI2
mutations, pituitary gland function was abnormal, accom-
paniedbyvariablecraniofacialabnormalities.Otherfeatures
included postaxial polydactyly, single nares, single central
incisor, and partial agenesis of the corpus callosum.
B. Combined pituitary hormone deficiency: genes
involved in pituitary cell differentiation
1. PROP1
As a result of the identification of Prop1 as the gene
underlyingtheAmesdwarfphenotype,thefirstmutations
inPROP1(OMIM601538)wereidentifiedinhumanpa-
tients with hypopituitarism characterized by GH, TSH,
and PRL deficiencies in addition to reduced gonadotro-
pins and failure to enter spontaneous puberty (246). Sub-
sequently, 26 distinct mutations have been identified in
more than 180 patients from over 21 different countries,
implicating PROP1 mutations as the most common ge-
netic cause of CPHD accounting for approximately 50%
of familial cases (247–249), although the incidence in
sporadic cases is much lower (247, 250). All affected
individuals exhibit recessive inheritance, and the ma-
jority of mutations identified involve the DNA binding
homeodomain,whichishighlyconservedbetweenhuman
and mouse, showing 91% identity at the nucleotide level
(246, 251). The mutations in PROP1 identified to date in-
clude nonsense, missense, frameshift, intronic, and deletion
mutations (Table 4). The majority of the mutations are pre-
dictedtoresultincompletelossoffunctionbyablatingDNA
binding and transcriptional activation, although some mis-
sensemutationsretainpartialactivity(246,252,253).Byfar
the most common mutation, accounting for 50–72% of all
familial PROP1 mutations in multiple unrelated families
(247,248,254),isa2-bpdeletionwithinexon2resultingin
a frameshift at codon 101 and the introduction of a termi-
nationcodonatposition109(oftenreferredtoasp.S109X).
The deletion occurs within three tandem GA repeats, so the
2 bp deleted cannot be defined; consequently this mutation
has been referred to as c.296delGA and c.301_302delAG in
different reports. This mutation is likely to represent a mu-
tational hot spot within the gene, rather than a common
foundermutation(247),andcombinedwiththeincidence
of the c.150delA mutation, accounts for approximately
97% of all known PROP1 mutations.
Homozygosity for mutations in PROP1 is typically as-
sociated with a deficit of GH, TSH, PRL, and gonadotro-
pins, although the time of onset and severity of hormone
deficiency varies. Most patients present with early-onset
GH deficiency and growth retardation; however, normal
growth in early childhood has been reported in a patient
whoattainednormalfinalheightwithoutGHreplacement
therapy(255,256).Inthiscase,thepatientpresentedwith
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monedeficiencieslaterinlife.TSHdeficiencyisalsohighly
variable and has been reported as the initial presenting
symptom in some cases (248, 257, 258), whereas other
patients show delayed onset (257, 259). Onset of ACTH
deficiency is significantly correlated with increasing age,
and most patients exhibit normal ACTH and cortisol lev-
els in early life (260–263); however, patients as young as
6 yr have been described with cortisol deficiency empha-




man gonadotropin deficiency is extremely variable in pa-
tients with PROP1 mutations, ranging from early hypo-
gonadism with a micropenis and undescended testes and
complete lack of pubertal development to spontaneous,
albeit often delayed, onset of puberty with subsequent
deficiency of gonadotropins, requiring hormone replace-
menttherapy(248,257,259,262).Variationinthetiming
and severity of gonadotropin deficiency could mean that
hypogonadism in patients with PROP1 mutations is ac-
quiredandlateevolvingratherthanearlycongenital,con-
sistent with a role for PROP1 in maintenance or terminal
differentiation of gonadotropes rather than initial speci-
fication (266). However, a number of individuals with
mutations may have congenital gonadotropin deficiency,
given the presence of a micropenis and bilaterally unde-
scended testes at birth (250).
ThepituitarymorphologyinpatientswithPROP1mu-
tationsisunpredictable;mostcasesshowahypoplasticor
normal-sized anterior pituitary gland on imaging, with a
normal pituitary stalk and posterior lobe, although some
reportshavedocumentedanenlargedanteriorgland(246,





poplasia, although the size of the pituitary can wax and
wane during this time (Fig. 4F) (250, 258, 263). The pi-
tuitary enlargement consists of a mass lesion interposed
between the anterior and posterior lobes, possibly origi-
natingfromtheintermediatelobe(258)orRathke’spouch
remnant in the cleft, although the underlying mechanism
for the mass remains unknown. Evidence from the mouse
(see above) suggests that PROP1 regulates the migration
of progenitor cells from Rathke’s pouch into the develop-
ing anterior pituitary, and in the absence of functional
PROP1, undifferentiated cells are trapped in the perilu-
menal area resulting in enlargement of the anterior pitu-
itary followed by apoptosis (152). Such a mechanism
wouldbeanattractiveexplanationforthehumanimaging
findings, but of course would be difficult to establish and
cannot account for the waxing and waning of the mass.
Earlier biopsies of such a mass failed to reveal any defin-
itive histopathology, with no cell types identified (266),
andsuchmaterialisnowlikelytoproveelusivebecausethe
TABLE 4. Reported mutations in the PROP1 gene
Nucleotide change Location Type of mutation Effect on protein Ref.
c.2TC Exon 1 Missense (initiation codon) No translation 299
c.109  1GT Intron 1 Splice site Aberrant splicing 265
c.112_124del13 Exon 2 Frameshift Premature truncation 264
c.149_150delAG Exon 2 Frameshift Premature truncation 300
c.150delA Exon 2 Frameshift Premature truncation 263
c.157delA Exon 2 Frameshift Premature truncation 301
c.211CT Exon2 (HD) Missense p.R71C 302
c.212GA Exon2 (HD) Missense p.R71H 302
c.217CT Exon 2 (HD) Missense p.R73C 248, 251
c.218GA Exon 2 (HD) Missense p.R7
3H 259
c.247CT Exon 2 (HD) Nonsense p.Q83X 303
c.263TC Exon 2 (HD) Missense p.F88S 252
c.295CT Exon 2 (HD) Nonsense p.R99X 259
c.296GA Exon 2 (HD) Missense p.R99Q 304
c.296_297delGA c.301_302delAG Exon 2 (HD) Frameshift Premature truncation 246
c.310delC Exon 2 Frameshift Premature truncation 253
c.343–11CG Intron 2 Splice site Aberrant splicing (loss of exon 3) 253
c.343–2AT Intron 2 Splice site Aberrant splicing 251
c.349TA Exon 3 (HD) Missense p.F117I 246
c.358CT Exon 3 (HD) Missense p.R120C 246, 257
c.373CT Exon 3 Missense p.R125W 253
c.467insT Exon 3 Frameshift Premature truncation 305
c.582GA Exon 3 Nonsense p.W194X 255
c.629delC Exon 3 Frameshift Altered transactivation domain at codon 210 306
HD, Homeodomain.
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identified PROP1 mutations.
The evolving nature of hormone insufficiencies in pa-
tients with PROP1 mutations suggests a progressive de-
clineintheanteriorpituitaryaxis,sosuchpatientsrequire
regular monitoring for the development of hormone def-
icits that may not be apparent on initial presentation. The
highly variable nature of the phenotype associated with
PROP1mutations,evenbetweensiblingswithinthesame
family carrying identical mutations (253, 257), together
with the observation of phenotypic differences in Prop1
mutant mice on different genetic backgrounds, again im-
plicate unidentified genetic modifiers playing a role in the
severity and onset of disease pathogenesis.
2. POU1F1 (PIT1)
Mutations within POU1F1 (PIT1; OMIM 173110)
were first reported in 1992 by four independent groups
(268–271) and are generally associated with GH, PRL,




can be highly variable. The majority of cases present with
early TSH deficiency; however, in some cases hypothy-
roidism occurs later in childhood (269, 272, 273). We
have recently described a 21 yr old with GH and PRL
deficiency who has normal thyroid function to date (274)
with a POU1F1 mutation identical to that found in an
unrelated patient who developed central hypothyroidism
in the second year of life. MRI of patients with POU1F1
mutations demonstrates a small or normal-sized anterior
pituitary gland with a normal posterior pituitary and in-
fundibulum, but with no extrapituitary abnormalities
(Fig. 4E). A total of 28 different mutations in POU1F1
have been described to date; 23 of these show recessive
inheritance, including a complete gene deletion and a re-
centreportofasplicesitemutation(275),whereasfiveare
dominant mutations, found in over 60 patients from sev-
eral different countries (Tables 5 and 6). Of these, the
amino acid substitution p.R271W is the most frequent hav-
ingbeenidentifiedinseveralunrelatedpatientsfromavariety
of different ethnic backgrounds (270, 271, 276–282).
The p.R271W mutant protein is capable of binding to
DNA and appears to act as a dominant-negative inhibitor
of transcription by wild-type POU1F1 (PIT1) protein
(270, 283), although this has been disputed (284). The
only other mutations reported in more than one pedigree
aretherecessivelyinheritedmutationsp.R172X(reported
in three pedigrees) (268, 273, 285), p.A158P (two pedi-
grees) (269), p.P239S (three pedigrees) (286), and
p.E230K identified in five pedigrees from three different
countries (274, 287). Studies of POU1F1 in CPHD pa-
tient cohorts suggest that the incidence of mutations in
cases of sporadic CPHD is quite low (approximately
3–6%), whereas the incidence among familial patients
with hypopituitarism is much greater (25%) (274, 288).
Functional analysis has been performed for a relatively
small number of mutations and has revealed effects on
DNA binding (274), protein-protein interactions [p.S179R
mutation (289)], and retinoic acid induction of the
Pou1f1 (Pit1) gene distal enhancer either alone or in com-
bination with wild-type POU1F1 (PIT1) [dominant-
negative p.K216E mutation (290)]. Further analysis is
required to understand the molecular mechanisms under-
lying mutations such as the dominant-negative p.P14L
and p.P24L mutations.
C. TBX19 and ACTH deficiency
Several recessive mutations have been identified in the
TBX19 (TPIT) gene located at 1q23–24, encoding the
transcription factor TBX19 (TPIT), resulting in severe
ACTH deficiency, profound hypoglycemia associated
with seizures in some cases, and prolonged cholestatic
jaundiceintheneonatalperiod.MutationswithinTBX19
(TPIT) were initially identified in two patients who pre-




mutation Location Inheritance Ref.
p.Q4X Nonsense Exon 1 Recessive 307
p.P14L Missense Exon 1 Dominant 308
p.P24L Missense Exon 1 Dominant 271
p.F135C Missense Exon 3 Recessive 272
p.R143Q Missense Exon 3 Recessive 271
p.R143L Missense Exon 3 Recessive 288
p.K145X Nonsense Exon 3 Recessive 309
p.A158P Missense Exon 4 (POU) Recessive 310
p.Q167K Missense Exon 4 (POU) Dominant 311
p.R172Q Missense Exon 4 (POU) Recessive 274
p.R172X Nonsense Exon 4 (POU) Recessive 268
p.E174G Missense Exon 4 (POU) Recessive 285
p.W193R Missense Exon 4 (POU) Recessive 312
p.W193X Nonsense Exon 4 (POU) Recessive 287
p.L194Q Missense Exon 4 (POU) Recessive 288
c.682  1GA Splice site Intron 4 recessive 275
p.K216E Missense Exon 5 Dominant 290
p.E230K Missense Exon 6 (HD) Recessive 287
p.F233L Missense Exon 6 (HD) Recessive 313




Frameshift Exon 6 (HD) Recessive 314
c.747delA Frameshift Exon 6 (HD) Recessive 312
p.E250X Nonsense Exon 6 (HD) Recessive 315
c.778insA Frameshift Exon 6 (HD) Recessive 274
p.F262L Missense Exon 6 (HD) Recessive 314
p.R271W Missense Exon 6 (HD) Dominant 270
p.V272X Nonsense Exon 6 (HD) Recessive 317
HD, Homeodomain; POU, POU specific.
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Gene Protein




HESX1 HESX1 Anophthalmia or microphthalmia,
agenesis of corpus callosum,
absence of septum pellucidum,
pituitary dysgenesis or aplasia
Variable: SOD, CPHD, IGHD with
EPP. Anterior pituitary hypoplastic
or absent. Posterior pituitary
ectopic or eutopic
Dominant or recessive in
humans, recessive in
mouse
Frequency of mutations: 1% (199)




























Heterozygous mice and further




reduction in all cell types
Frequency of mutations: 8/235
(103); 10% (212)








of mutations 6% (duplications),
1.5% (mutations) (220)
X-linked recessive in both
mice and humans
GLI2 GLI2 N/A Holoprosencephaly, hypopituitarism,
craniofacial abnormalities,
polydactyly, single nares, single
central incisor, partial ACC
Haploinsufficiency
Frequency of mutations: 1.5% (245) In humans
LHX3 LHX3 Hypoplasia of Rathke’s pouch GH, TSH, gonadotropin deficiency
with pituitary hypoplasia. ACTH




Frequency of mutations: 1.3% (225)
LHX4 LHX4 Mild hypoplasia of anterior
pituitary
GH, TSH, cortisol deficiency,
persistent craniopharyngeal canal





Frequency of mutations: 1.2% (235)





GH, TSH, PRL, and gonadotropin
deficiency. Evolving ACTH
deficiency. Enlarged pituitary with
later involution
Recessive in both
Frequency of mutations: 1.1%
sporadic cases, 29.5% familial
cases (250)
POU1F1 POU1F1 (PIT1) Anterior pituitary hypoplasia with
reduced somatotropes,
lactotropes and thyrotropes
Variable anterior pituitary hypoplasia





Frequency of mutations: 3.8%
sporadic cases, 18% familial cases
(274)
ACC, Agenesis of the corpus callosum; APH, anterior pituitary hypoplasia; EPP, ectopic posterior pituitary; N/A, not available.
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ficiency (23), with very low basal plasma cortisol concen-
trations and no ACTH response to CRH, but a cortisol
responsetocorticotropinadministration.Consistentwith
its pituitary expression restricted to POMC cells, muta-
tionsinTBX19(TPIT)arefrequentlyassociatedwithneo-
natal isolated ACTH deficiency, but never with cases of
juvenile onset deficiency. Twelve independent mutations
havebeenidentified,includingnonsense,missense,frame-
shift, and splicing mutations in addition to a 5.2-Kb
genomic deletion encompassing exons 2 and 3 (23, 291–
294). All of these mutations have been shown or are pre-
dicted to result in loss of TBX19 (TPIT) function (291,
292), and all patients appear to be homozygous or com-
pound heterozygous for TBX19 (TPIT) mutations, with
unaffected heterozygous parents, implying a recessive
mode of inheritance.
Vallette-Kasic et al. (292) have reported the largest se-
riestodateanddemonstratedTBX19(TPIT)mutationsin
17 of 27 patients from 21 unrelated families, suggesting
that mutations in this gene are the principal molecular
cause of congenital neonatal isolated ACTH deficiency.
Three patients carry only one mutant TBX19 (TPIT) al-
lele, although their family history implied recessive inher-
itance, so additional, as yet unidentified, mutations may
be present in regulatory regions of the gene in some cases
(292). In contrast with most other developmental gene
mutations, TBX19 (TPIT) mutations present a relatively
selective endocrine phenotype with normal function of all
otherpituitaryaxes.Severehypoglycemia,associatedwith
seizuresandfailuretothriveinsomecases,andprolonged
cholestatic jaundice are classically associated with ACTH
deficiency presenting in the neonatal period (23, 292).
Furthermore,Vallette-Kasicetal.(292)notedthatintheir
series about 25% of families with segregating TBX19
(TPIT) mutations (five of 21) suffered a neonatal death,
suggesting that isolated ACTH deficiency may be an un-
derestimated cause of this.
VII. Conclusion
Over the past decade, there has been an explosion in the
knowledge of the genetic cascade that orchestrates hypo-
thalamo-pituitarydevelopment.Severaltranscriptionfac-
tors and signaling molecules are critical for organ com-
mitmentandcelldifferentiationandproliferationatavery
early stage of gestation. Knowledge of the expression pat-
ternofthesegeneshashelpedexplainthewiderphenotype
in patients with hypopituitarism, for example those with
SOD who have associated forebrain and eye defects. The
mousehasservedasanexcellentmodelforunderstanding
thegeneticbasisofcongenitalhypopituitarisminhumans,
although the correlation between mouse and human
diseasephenotypesisvariable(Table6).Thiscandidate
gene approach, based on mouse studies, has led to the
identification of several human mutations that disrupt
hypothalamopituitarydevelopmentresultinginspecificpat-
ternsof hormonedysfunction.However,therearemany
genes that remain to be identified and in future will
enable more extensive screening of the large number of
patientswholackadefinitiveetiology.Ourunderstand-
ing of the etiology and molecular mechanisms of these
disorders will undoubtedly lead to improvements in the
management of these patients.
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